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C-terminal binding proteins (CtBPs) are transcriptional co-repressors involved in 
developmental processes, and also implicated in a number of breast, ovarian, colon 
cancers, and resistance against cancer chemotherapy. CtBP is a validated novel 
potential anti-cancer target. In this project we sought to develop potent and selective 
small-molecule inhibitors of CtBP. Using a combination of classical medicinal 
chemistry and modern computational approaches, we designed a potent inhibitor 
HIPP (hydroxyimino-3-phenylpropanoic acid) that showed an IC50 of 0.24 µM against 
recombinant CtBP. Further elucidation of the structure-activity relationship (SAR) of 
HIPP led to the design of more potent inhibitors 3-Cl HIPP (CtBP IC50 = 0.17 µM) and 
4-Cl HIPP (CtBP IC50 = 0.18 µM). These compounds also showed inhibition in HCT-
116 colon cancer cells with GI50 values ~ 1-4 mM. The compounds showed no off-
xv 
 
 
 
target toxicity against a closely related protein. This is a starting point for the 
development of CtBP inhibitors as anti-cancer therapeutics.  
 
The second part of this dissertation focuses on C–H activation chemistry. C–H 
activation is the most atom-economical method of introducing complexity into a 
molecule, even at late stages of drug/product development. We have used solid-
supported palladium nanoparticle catalyst (Pd-MWCNT) to investigate the scope of 
C–H activation reactions it can catalyse. Pd-MWCNT was found to efficiently catalyse 
N-chelation directed C-H activation reactions – halogenations, oxygenations and 
arylations. The turn-over numbers for these reactions were significantly higher than 
that of the reported homogenous catalyst. The added advantages of reuse/recyclability 
of catalyst, low contamination of metal in the final product make this catalyst very 
attractive on an industrial scale. This work serves as a foundation for the further 
development of Pd-MWCNT catalyst in late-stage synthesis of drugs and/or 
diversification of products.  
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Design and Structure-Activity Relationship Study of Small Molecule C-terminal 
Binding Protein (CtBP) Inhibitors 
1. Introduction 
 
1.1. Gene Regulation 
Gene expression is regulated by a combination of transcriptional activation and 
transcriptional repression. DNA sequence-specific transcriptional repressors recruit 
certain co-repressors to specific regions of DNA and inhibit gene expression of a single 
gene or multiple genes by targeting the transcriptional machinery or altering the 
chromatin structure. For example, several co-repressors recruit histone deacetylases 
(HDACs) to remove acetyl group from the N-terminal tails of histones, resulting in 
chromatin condensation, thereby preventing transcription factors access to DNA. 
Examples of HDAC-dependent corepressors include Sin3, pRb, Groucho, Mi-
2/NuRD.1 Proper gene regulation through transcriptional regulation allows cells to 
respond to stimuli, whereas improper gene regulation results in disease states. 
Molecular control of the transcriptional machinery complex is a highly challenging 
area, the investigation of which would help in the advancement of cancer therapy. This 
dissertation focuses on CtBP (C-terminal Binding Protein) – transcriptional 
corepressors, which have been implicated in development and oncogenesis. 
Targeting CtBP has been shown to relieve the repression of apoptotic genes, tumor 
suppression genes and genes involved in cell adhesion. This dissertation focuses on 
the development of small molecule inhibitors that target CtBP and show potential as 
novel anti-cancer therapeutics. 
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1.2. CtBP 
The CtBP family of proteins function as transcriptional co-repressors and are highly 
conserved among vertebrates and invertebrates. CtBP plays an important role during 
early development, and has been implicated in various cancers. It modulates the 
activity of oncogenes and tumor suppressor genes. CtBP represses transcription by 
both chromatin modification-dependent and independent pathways, depending on the 
promoter. CtBP proteins also act as a link between gene expression and metabolism, 
as their transcriptional regulation function is dependent on the intracellular 
NAD+/NADH ratio. 
1.2.1 Discovery 
CtBP is a 48 kDa cellular phosphoprotein (441 amino acids) that was first identified in 
1993 by its binding to the C-terminal region (PLDLS motif) of E1A human adenovirus 
oncoprotein,2, 3 during a search for proteins involved in negative modulation of 
oncogenic transformation. This initial isoform was named CtBP1. CtBP2 (445 amino 
acids, 48 kDa, 83% sequence homology to CtBP1) was identified by analysing 
expressed sequence tag (EST) data bank sequences.4  
1.2.2. Isoforms and genes 
Invertebrates possess a single CtBP gene. They have different isoforms of CtBP as a 
result of differential RNA processing. Vertebrates possess CtBP1 (Ctbp1 gene 4p16 
chromosome) and CtBP2 (Ctbp2 gene 21q21.3 chromosome).4 Both vertebrate genes 
code for different CtBP isoforms – CtBP-L (long) and CtBP-S (short).  
CtBP1-S lacks the first 13 amino acids of the CtBP1-L N-terminal domain. CtBP1-S is 
also known as CtBP3/BAR50, is N-terminally truncated CtBP1, which has 
acyltransferase activity in Golgi.5 
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CtBP2-S does not possess the first 25 amino acids of the CtBP2-L N-terminal domain. 
In the retina, a form of CtBP2 called RIBEYE protein (120 kDa) is expressed.6, 7 It has 
an N-terminal domain fused to CtBP2 (amino acids 21-445). 
1.2.3. Localization 
CtBP isoforms are present in nucleus or cytoplasm based on the post-translational 
modifications and the presence/absence of nuclear localization signal (NLS). The NLS 
sequence is KRQR and corresponds to the residues 10-13 of hCtBP2. CtBP2-L can 
heterodimerize with CtBP1 and translocate CtBP1 to the nucleus. CtBP1 isoforms do 
not have NLS sequence, and are concentrated in the nucleus, significant quantities 
are present in the cytosol. Neuronal nitric acid synthase (nNOS) binds to CtBP1 and 
translocates it to the cytoplasm from the nucleus.8 CtBP2-S lacks the NLS sequence, 
and hence is localised in the cytoplasm.9 Localization is not solely dependent on NLS, 
as CtBP2-L dimer interface mutants localise in the cytoplasm.10 RIBEYE is localized 
in the cytoplasm and is mainly present in the ribbon synapses.6, 11 , 12 The localization 
of CtBP depends on the post-translational modifications, and is not consistent 
throughout the literature. CtBP1-L and CtBP-1S have been observed both in 
cytoplasm and nucleus.9 Phosphorylation of S158 by Pak1 kinase translocates CtBP1 
to the cytoplasm, and inhibits the corepressor activity of CtBP1.13  
SUMOylation of K428 by SUMO-1 (blocked by nNOS) localises it in the nucleus and 
is required for corepression of E-cad by CtBP1.14  Dimerization, which is dependent 
on NADH binding, also affects nuclear localization. Inhibition of CtBP dimerization 
prevents nuclear localization.15 
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1.2.4. Oligomerization 
CtBP forms dimers through the dehydrogenase domain similar to D-isomer specific 
NAD-dependent 2-hydroxy acid dehydrogenase (D2-HDH) family members. 
Oligomerization has been observed in bacterial D2-HDH enzymes – D-Lactate 
Dehydrogenases16, 17 Hydroxyisocaproate Dehydrogenase,18 Formate 
Dehydrogenase,19 D-Glycerate Dehydrogenase,20 and in human D2-HDH enzymes – 
Glyoxylate Reductase/Hydroxypyruvate Reductase21 and D-3 Phosphoglycerate 
Dehydrogenase.   
CtBP is a redox sensor as its activity is dependent on the metabolic status of the cells 
– NADH/NAD+ ratio. It binds to NADH with a 100-fold more affinity than NAD+.22 Once 
NADH binds to CtBP, the protein undergoes dimerization,23 which is essential for the 
activity of CtBP.10, 24-26 When NADH levels increase – conditions of hypoxia and high 
extracellular glucose levels – NADH binds to CtBP, and the activity of CtBP increases.  
Each monomer of CtBP contains a single PXDLS motif to which other proteins bind. 
The presence of a single monomer results in competition between different factors 
binding to CtBP, which disrupts transcriptional regulation.10 Dimerization of CtBP 
increases the number of PXDLS sites, thereby providing a scaffold for other 
transcriptional factors to bind. CtBP1 dimerization is required for its interaction with 
E1A protein. NADH mediated dimerization enhances repression activity of CtBP. 
CtBP1 mutants that cannot dimerize fail to effect transcriptional repression. NADH has 
been found to be essential for dimerization and hence nuclear localisation, but not for 
binding of other factors. Binding of other factors depends on the PXDLS motif. 
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1.2.5. CtBP Domain Arrangement 
CtBP is highly homologous to D-isomer specific NAD-dependent 2-hydroxy acid 
dehydrogenases (D2-HDH) – catalytic Histidine residue, Arg, Glu, and an NAD-binding 
region (Figure 1-1).3 It has 3 domains – C-terminal domain, dehydrogenase domain 
and N-terminal domain. The dehydrogenase domain has two domains – substrate 
binding domain and coenzyme binding domain. Two features of CtBP that are involved 
in recruiting cofactors/proteins are: 
a. Hydrophobic cleft formed by N-terminal region in CtBP1-L (AA 27-121) that 
recruits PLDLS motif containing factors (DNA binding proteins). 
b. Surface groove on NADH-binding domain that recruits RRT motif containing 
factors 
C-terminal unstructured region has sites for SUMOylation and PDZ (structural domain  
80-90 AA) binding. 
 
Figure 1-1. Structural Features of CtBP15 
CtBP1-L has the entire CtBP sequence, CtBP1-S has a truncation (blue region) in the 
N-terminal region. In CtBP2-S, this truncation (25 AA) causes loss of NLS sequence, 
thus localising it to the cytoplasm. D2-HDH domain has a substrate binding domain 
(yellow, has PXDLS-binding motif), and coenzyme NADH binding domain (green, has 
RRT-binding motif and catalytic triad REH), which are connected by hinges (Figure 1-
1). 
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1.3. Cytosolic and Nuclear functions of CtBP 
1.3.1. Nuclear functions  
CtBP forms large DNA-bound chromatin remodelling complexes and is involved in 
transcriptional regulation (Figure 1-2). CtBP is recruited to DNA by several DNA 
binding proteins through PXDLS-binding motif (substrate binding domain of N-terminal 
region) of CtBP. DNA-binding proteins such as ZEB 1/2 (zinc finger protein) function 
as bridges between CtBP PXDLS-binding motif and the promoters (for example E-
cadherin).10, 27-31 CtBP coenzyme binding domain has RRT binding motif 
(RRTGXPPXL) that binds to cofactors that are involved in repression.32 Znf217 binds 
to CtBP through both PXDLS motif and RRT motif,15, 33 thus it binds to CtBP dimers 
(RRT-binding motif of one monomer, and PXDLS-binding motif of the second 
monomer).  
Numerous chromatin modifying proteins have been observed in CtBP transcriptional 
complexes. It has been seen that class I HDACs – HDAC 1/2 and class II HDAC 
proteins interact with CtBP.15, 34, 35 Other proteins such as HMT (Histone Methyl 
Transferase), LSD-1 (Lysine Demethylase), G9A, GLP bind to the CtBP complex.15, 34   
Histone-modifying proteins bind to CtBP either through other proteins or bind directly. 
HDAC1/2, CoREST (corepressor of REST) bind directly through non-PXDLS 
interactions.15, 34 CoREST recruits both HDAC1/2 and LSD-1 to CtBP.36, 37 However 
LCoR corepressor interacts through PXDLS motif of CtBP to recruit HDAC1/2.38 Some 
examples of chromatin modifying complexes include: Znf217 binding to CoREST that 
recruits HDAC1/2 and LSD-1 to CtBP;33 Wiz protein that binds to G9A/GLP and CtBP 
directly.39 Thus, depending on the context, various histone modifying proteins are 
recruited through different DNA-binding proteins in different CtBP multi-subunit 
regulatory complexes to regulate transcription.10 
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                    Figure 1-2. Multi-protein complexes with CtBP  
1.3.2. Cytosolic functions  
CtBP1 and CtBP2 play an important role in Golgi fission,40 vesicle formation41 and 
synapse signalling.11, 42 CtBP1-S has functions in the Golgi – tubule constriction and 
fissioning43 using acyl-coenzyme A (acyl-CoA) molecules. CtBP1-S also has acyl 
transferase activity towards lysophosphatidic acid (LPA) and alters the membrane 
properties in Golgi.5, 44 RIBEYE also has acyl transferase activity42 and is involved in 
vesicle formation at ribbon synapses.6, 11, 42 
1.4. CtBP as a Transcriptional Corepressor 
The transcriptional repression role of CtBP was first suggested in a tethering 
transcriptional assay45 involving E1A protein.  Interaction of CtBP with the C-terminal 
region of E1A inhibited the activity of conserved region 1 (CR1) of E1A. In-depth 
studies on Drosophila CtBP (dCtBP) showed that dCtBP functions as a transcriptional 
corepressor during development of embryo.30, 46 dCtBP has been found to interact with 
Knirps, Snail (short range repressors) and Hairy (long range repressors). CtBPs have 
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been shown to be recruited through PLDLS motif by several DNA-binding 
transcriptional repressors.27, 31 CtBPs exert their transcriptional regulation by 
interacting with DNA-binding repressors that have PLDLS motifs and chromatin 
modifying proteins (HDACs-1 that do not contain PXDLS motif). CtBPs form a 
hydrophobic cleft that interacts with both PXDLS and non-PXDLS containing factors. 
In vertebrates, mouse CtBP2 (mCtBP2) has been found to interact with mouse basic 
Kruppel-like factor (BKLF). This was dependent on PXDLS motif in the repressor 
domain. mCtBP1 has been found to interact with Net – Ets family transcriptional 
repressor.47 Several CtBP-interacting proteins have been identified through a two 
hybrid screening study.48  
1.4.1. Mechanism of Transcriptional Repression by CtBP 
The exact mechanism by which CtBP mediates transcriptional repression is not yet 
clear. It can occur in a HDAC-dependent or –independent manner. hCtBP1 has been 
reported to associate with HDAC1 in cotransfection experiments,49 with endogenous 
HDAC2 and Sin3.50 Repression of certain promoters by CtBP has been reported to be 
affected by trichostatin A (TSA, HDAC inhibitor), such as c-fos promoter repression by 
Net; whereas repression of SV40 promoter by pRb and p130 is not affected by TSA.51, 
52  
pRb and p130 are involved in HDAC-independent repression by recruiting PcG 
complex through CtIP and CtBP. Human polycomb protein hPC2 has been shown to 
interact with hCtBP1 and hCtBP2.53 CtIP is an adaptor protein that interacts with both 
pRb, p130 proteins (Rb binding motif, LXCXE) and with CtBP (PXDLS motif), thus 
linking both families of proteins. Thus, mammalian CtBPs repress transcription either 
through HDACs or through PcGs (Figure 1-327). 
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In Drosophila, the involvement of deacetylases in dCtBP-mediated repression is 
uncertain. The activity of dCtBP is not significantly affected in Rpd3 (HDAC 
mammalian homolog) mutant embryos.54 The mutant embryos might be expressing 
other deacetylases. 
In contrast to the repressor functions, dCtBP has also been shown to possess context-
dependent weak transcriptional activational functions.55 This activation has been 
observed in human HEK293 cells expressing E1A proteins. In the context of Hairy, 
dCtBP might be antagonizing the activity of Gro.46 The regions of dCtBP that are 
required for activation (His residue) and repressor functions are adjacent to each 
other.  
The corepressor complex of CtBP causes deacetylation and methylation of histone 
H3-K9, demethylation of histone H3-K4.  
Figure 1-3. Corepressor complex of CtBP (ref 27) 
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1.5. Regulation of CtBP Activity 
CtBP is a phosphoprotein, its phosphorylation is cell-cycle dependent. It possess 
consensus phosphorylation sites of DNA-PK (TQ or SQ) and has been found to 
interact with DNA-PK.48, 56 Phosphorylation changes the localization of CtBP. The 
activity of CtBP is also modulated by cellular energy levels/homeostasis as it binds to 
NAD. CtBP binding to E1A C-terminal region is regulated by the nuclear acetylases 
p300/CBP and P/CAF that acetylate the Lys residue (PLDLSCK) flanking CtBP binding 
motif of E1A,57 resulting in decrease of CtBP binding.  
1.6. Role of CtBP 
CtBP plays an important role in development and oncogenesis  
1.6.1. Role in Development 
In Drosophila, dCtBP is involved in transcriptional regulation and plays an important 
role during early embryo development and also during later developmental 
processes.58, 59 The CtBP gene is involved in regulatory functions in the wing,60 eye,61, 
62 sensory organs.63 Decrease in the levels of dCtBP leads to severe segmentation 
defects, disruptions in anterior-posterior patterning.46 This is a result of loss of 
repression of genes – eve, runt and hairy by short range repressors Knirps, Snail and 
Kruppel. A transcriptional repressor Tramtrack69 (Ttk69) binds to dCtBP and acts as 
a neural inhibitor during early eye development. This interaction determines the 
number of photoreceptor cells produced.64 
 
In Xenopus, the transcription factors xTcf-3, xFOG, xPc have been shown to interact 
with xCtBP. xCtBP is involved in the development and is localized in the head, tail bud 
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and in central nervous system.65 xFOG represses RBC formation partially by 
interacting with xCtBP.66 
In mammals, mCtBP2 is expressed during embryogenesis, and mCtBP1 is expressed 
throughout.67 CtBP1 is expressed in spinal chord, and CtBP2 is expressed in spinal 
chord, limb buds, and root ganglia. Mutation in CtBP2 causes embryonic lethality.68 
CtBP1-null mice are smaller in size than the wt mice, and have about 23% mortality 
rate after birth within 20 days.68 
 
In humans, both hCtBP1 and hCtBP2 are ubiquitously expressed in most human 
tissues.53 TGIF is a transcriptional repressor of TGF-β activated genes. It binds to 
CtBP protein. Mutations in TGIF leads to holoprosencephaly – brain malformations, 
due to the loss of interaction with hCtBP1. The wt huntingtin protein mediates 
transcriptional repression by interacting with CtBP.69 In Huntington’s disease (HD), the 
protein contains polyglutamine expansion, which leads to reduced interaction with 
CtBP, possibly leading to HD. 
1.6.2. Role of CtBP in Oncogenesis 
CtBP has been shown to bind to more than 1,800 promoters throughout the 
mammalian genome.70 CtBP has been linked to the development of cancer in the 
context of EMT (epithelial-to-mesenchymal) transition. EMT transition is an essential 
process during development, in which epithelial cells lose cell adhesion property and 
polarity, and acquire migratory, invasive properties.71 Though EMT is essential for 
wound healing and during development, it increases the resistance to apoptosis and 
metastasis of malignant tumors.72  
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CtBP has been shown to repress the transcription of pro-apoptotic factors,73 tumor 
suppressors,74 cell adhesion molecules – E-cadherin,73 cell-cell junction proteins and 
cytoskeletal proteins. Transcriptional repression of E-cadherin causes EMT. CtBP has 
been shown to play a role in the progression of melanoma,75 pituitary tumors,76 
prostate cancer,77 colon cancer78-83 and breast cancer.70, 84-87 
 
Levels of CtBP are regulated by tumor suppressors, disruption of which leads to 
cancers. In colorectal tumors, mutations in the tumor suppressor APC (adenomatous 
polyposis coli) have been observed.88 APC degrades CtBP1.78 The levels of APC and 
CtBP1 are inversely correlated during cancer initiation.78, 79  
ARF is another tumor suppressor which targets CtBP for proteosomal degradation. 
Binding of ARF to CtBP relieves the repression of a pro-apoptotic factor Bik.81 Bik 
inhibits the function of anti-apoptotic factors, and sensitizes cells to apoptosis.89 
Samples of colon cancer tissue showed high levels of CtBP and low levels of ARF, 
whereas adjacent healthy tissues showed low levels of CtBP and normal levels of 
ARF.83   
In colon cancer cells, increase in NADH levels due to hypoxia increased cell 
migration.24, 82 ARF antagonizes the function of CtBP, leading to Bik-mediated 
apoptosis. Hence, loss of APC and ARF increases CtBP levels and activity leading to 
tumorigenesis.  
The role of CtBP in breast cancer has been highly studied. Depletion of CtBP stops 
cell growth, whereas elevated CtBP levels lead to cell survival and metastasis. 
Elevated CtBP1 levels have been observed in invasive ductal carcinoma tissues.85 
Breast cancer cells show loss of E-cadherin, and low levels of the DNA repair protein 
BRCA1 breast cancer gene. Knockdown of CtBP restores the levels of E-cadherin and 
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BRCA1.85 Decrease in the NADH/NAD+ ratio removes HDAC1 for the promoter, 
leading to increase in BRCA1 levels.86 This might be the result of failure of CtBP 
dimerization under low NADH levels, and failure to form a repressor complex. This is 
the opposite effect of the “Warburg effect” in which high glycolysis increases NADH 
levels leading to increased CtBP activity in cancers.90, 91 CtBP knockdown reduces cell 
proliferation and sensitizes breast cancer cells to Cisplatin.84 Thus, breast cancer 
involves downregulation of E-cadherin and BRCA1 by CtBP. CtBP-mediated 
repression might be resulting in BRCA1 loss even in the absence of BRCA1 
mutation.86   
 
CtBP has been shown to be involved in oncogenesis through multiple 
mechanisms/pathways explained below. 
1.6.2.1. E1A Model – Tumor suppressor role  
CtBP negatively regulates oncogenesis by interacting with E1A protein. E1A mutants 
that lack the CtBP binding motif (PLDLS) in the C-terminal region cooperate with 
activated Ras oncogene, and cause high-frequency in vitro transformation of primary 
rat kidney cells.2, 3, 92 The resulting cells (E1A mutants) are very tumorigenic in mice 
models, and the tumors are metastatic. There are three possible pathways by which 
CtBP negatively regulates oncogenesis through E1A interaction (Figure 1-4):  
a). Interaction of CtBP with the PLDLS motif in the C-terminal region might antagonise 
the acetyl transferase activities of p300/CBP and P/CAF. This would result in the 
inhibition of cell proliferation activity of the N-terminal region. It has also been shown 
that pRb is acetylated by the E1A complex, which increases interaction between pRb 
and Mdm2,93 resulting in the inactivation of pRb.94 
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b). CtBP interaction with E1A represses certain cellular genes. Acetylation of Lys 
residues or deletion of the CtBP-interacting region (PLDLS motif) relieves repression. 
c). wt E1A competitively interacts with CtBP and relieves the repression in 
endogenous repression complexes resulting in the activation of certain genes that 
modulates oncogenesis,49, 95, 96 whereas mutant E1A fails to relieve the repression.  
 
 
1.6.2.2. Wnt Signaling Model – Tumor suppressor role 
In mammals, CtBP might be playing a role in the Wnt signalling pathway during 
development and oncogenesis. In the absence of Wnt signalling pathway, APC tumor 
Figure 1-4. Negative regulation of oncogenesis by CtBP through E1A (ref 27) 
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suppressor protein degrades β-catenin; and hTcf-4 functions as a constitutive 
repressor of Wnt target genes. hTcf-4 has two binding motifs for CtBP binding. When 
Wnt signalling is activated, β-catenin levels increase. β-catenin binds to hTcf-4, 
recruits the p300/CBP coactivator, which activates Wnt target genes cMyc, cyclin D1 
resulting in oncogenesis. Mutations in APC and β-catenin have been shown to cause 
tumorigenesis. Oncogenic mutations increase β-catenin levels. Mutations that affect 
interaction of CtBP with hTcf-4 might contribute to colorectal carcinogenesis.97, 98 CtBP 
might be contributing to the transcriptional repression activity of hTcf-4, and 
antagonizing the β-catenin/CBP coactivator complex activity.  
1.6.2.3. Evi-1 oncogene – Oncogenesis role 
Evi-1 is a nuclear protein that functions as a sequence-specific transcriptional 
repressor. It inhibits TGF-β signalling by causing repression of Smad-induced 
transcription of TGF-β responsive genes,99 resulting in cell proliferation. Evi-1 is a 
cellular oncogene that has been implicated in myeloid leukemogenesis in humans and 
mice. It is highly expressed in human myeloid leukemias and in chronic ML. Evi-1 
repressor domain contains two CtBP binding motifs. Mutants in these motifs do not 
bind well with CtBP and fail to cause transcriptional repression.100, 101 CtBP might be 
playing an important role in Evi-1 mediated leukemogenesis. 
1.6.2.4. Ras signalling 
CtBP modulates the activity of Net belonging to the family of Ets transcriptional 
repressors.47 Net is regulated by Ras. Net interacts with serum response element 
(SRE) and represses c-fos promoter. Ras signalling reverses this repression. Net 
recruits CtBP and mediates repressor activity in the absence of Ras.  
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1.7. Dehydrogenase Activity of CtBP 
CtBP is similar to the D2-HDH family of proteins. D2-HDH enzymes function by 
transferring a hydride anion to substrate by simultaneous NADH oxidation, and in that 
process convert the ketone carbonyl group of α-keto acid to hydroxyl group (Scheme 
1-1, Figure 1-5).18, 102, 103 Keto-acid portion of the substrate is stabilized by arginine by 
electrostatic interactions, glutamate makes hydrogen bonding interaction with histidine 
residue, histidine proton polarizes carbonyl oxygen. NADH transfers hydride anion to 
the carbon of substrate carbonyl group, carbonyl oxygen abstracts proton from 
histidine giving the D-hydroxyacid product. 
 
The dehydrogenase activity of CtBP was first discovered by its ability to convert 
pyruvate to lactate by oxidation of NADH.23, 104 Search for potential substrates resulted 
in the discovery of MTOB (4-methylthio-2-oxobutyric acid), as the putative 
endogenous substrate for CtBP. MTOB is an intermediate in the methionine salvage 
Figure 1-5. Mechanism of hydride transfer  
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pathway – following reduction, transamination of MTHB gives methionine.105 MTOB 
was found to be 80-fold better substrate for CtBP1 than pyruvate.106 When the sulfur 
in MTOB was replaced by a methylene group (2-oxohexanoic acid), the enzymatic 
activity reduced by 8-fold. Thus, sulfur is essential for selectivity.106  
 
The transcriptional regulation by CtBP does not require the dehydrogenase activity of 
CtBP, which suggests that NADH binding is conserved for the purpose of 
transcriptional regulation, and not for catalytic turnover.73  
Though MTOB is a better substrate for CtBP than pyruvate, it is still a poor substrate 
compared to the other D2-HDH family of proteins. For example, E. coli DGDH 
catalyses substrate 2600 times more efficiently than MTOB catalysis by CtBP.106-108 
1.8. Targeting CtBP to Treat Cancer 
Reports show that CtBP can be inhibited by high levels (millimolar) of putative 
substrate MTOB (shows bi-phasic kinetics), and that MTOB has anti-tumor effects in 
breast and colon cancer cells.83 Although MTOB was shown to have an apoptosis-
inducing effect earlier, its targets were not known at that time.109 Straza et al reported 
that MTOB at concentrations of around 4 mM displays cytotoxicity in HCT-116 cells. 
MTOB acts by displacing CtBP from the Bik promoter, thereby relieving Bik-mediated 
repression, finally resulting in apoptosis. MTOB has been shown to be effective in a 
mouse xenograft model using p53-/- HCT-116 cells, but it showed no effect in normal 
healthy mice, suggesting that it has no off-target toxicity issues. MTOB (10 mM) has 
Scheme 1-1. Reduction of MTOB by CtBP 
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been shown to have anti-cancer effect in MCF-7 and MDA-MD231 cells through 
inhibition of CtBP; it inhibited the repression of several genes associated with EMT 
and genome stability.75 These preliminary data provide insights into targeting CTBP to 
treat cancers. Other than the small molecule inhibitor MTOB, there are two other CtBP 
inhibitors reported – peptide inhibitor, and a small molecule inhibitor NSC95397.   
1.8.1. Peptide inhibitor of CtBP 
Birts et al. reported a CtBP dimerization cyclic peptide inhibitor – cyclo-SGWTVVRMY 
by high-throughput screening that assesses SICLOPPS (split-intein circular ligation of 
peptides and proteins)110, 111 cyclic peptide libraries (cyclic 
heptamer/octamer/nonamer) of about 64 million members (genetically encoded).112 
This study proved that CtBP dimerization links cellular metabolism with mitotic fidelity.  
The assay used a bacterial reverse two-hybrid system (RTHS) to analyse the link 
between bacterial (E. coli) survival on a selective media and disruption of CtBP1 
homodimer (NADH-dependent) fused to bacteriophage 434 repressor. The repressor 
434 (bacteriophage DNA binding protein) is reconstituted when CtBP1 fusion protein 
homodimerizes, leading to repressor binding to operator sites in E.coli chromosome, 
this prevents transcription of three downstream reporter genes (HIS3, Kan and LacZ), 
resulting in cell death in selective media. If the target proteins do not interact or when 
the protein-protein interaction is inhibited by an inhibitor, the reporter genes are 
expressed and cells survive in selective media (Figure 1-6). 
Above figure reproduced from “A cyclic peptide inhibitor of C-terminal binding protein dimerization links metabolism with mitotic 
fidelity in breast cancer cells,” C. N. Birts, S. K. Nijjar, C. A. Mardle, F. Hoakwie, P. J. Duriez, J. P. Blaydes and A. Tavassoli, 
Chem. Sci. 2013, 4, 3046. DOI: 10.1039/C3SC50481F - Published by The Royal Society of Chemistry. 
Figure 1-6. Bacteria reverse two hybrid system (ref 112) 
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The peptides contained these residues in common – serine (nucleophile for intein 
processing), glycine (prevents racemization during synthesis), tryptophan 
(chromophore for HPLC purification). Transformation was carried out on CtBP1 RTHS 
with SICLOPPS plasmids, split-inteins were expressed that underwent processing to 
give cyclic peptides. Only plasmids that produce cyclic peptides disrupting CtBP1 
homodimerization allow for cell survival on selective media. After picking bacterial 
colonies, plasmids were isolated and re-screened for non-specific inhibitors of the 
RTHS (by using a different RTHS system). The SICLOPPS plasmids which gave rise 
to three most potent peptides were sequenced for identity (Table1-1).  
 
 
 
 
 
 
CP61 (Figure 1-7) has been shown to disrupt CtBP 
dimerization both in vitro and in cells. It binds to CtBP1 (3 
µM affinity), inhibits CtBP homo- and heterodimerization 
with an in vitro IC50 of 19 ± 4 µM, but it requires fusion to 
a cell penetrating molecule to enter the cell. CP61 does 
not bind to the NADH-binding pocket of CtBP, so probably 
it is an allosteric inhibitor. It did not show any inhibition of 
LDH, thus it is very selective for CtBP. CP61 was used to establish that dimerization 
of CtBP regulates mitotic fidelity in cancer cells. In breast cancer cells with high rate 
Rank Name Target Peptide sequence 
1 CP61 CtBP1/CtBP2 SGW TVVRMY 
2 CP68 CtBP1/CtBP2 SGW PLSTWY 
3 CP65 CtBP1/CtBP2     SGW RLIRLY 
    
Table 1-1. Peptide inhibitors identified by SICLOPPS  
 Figure 1-7. Structure of CP61 
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of glycolysis, this compound reduced the mitotic fidelity, proliferation and colony 
formation; but had no effect in cells with lower rate of glycolysis. This provides 
evidence that the glycolytic state of cells is linked to mitotic cell cycle checkpoint 
control through NADH regulation/detection by CtBPs. This inhibitor of dimerization is 
important to study the roles of NADH-unbound CtBP. 
1.8.2. NSC95397 – A Small-molecule inhibitor of CtBP 
Blevins et al. reported a NSC95397, small molecule inhibitor of CtBP.113 They used a 
high-throughput screening assay (AlphaScreen) to screen LOPAC library (Sigma-
Aldrich, 1280 bioactive compounds), and found NSC95397 
(Figure 1-8) to be a good inhibitor of CtBP with an IC50 of 2.9 
µM (inhibits CtBP-E1A interaction).  
NSC95397 was found to be a weaker substrate of CtBP1 
compared to MTOB; and was not found to inhibit LDH. MTOB 
failed to inhibit CtBP-E1A interaction, in contrast NSC95397 inhibits CtBP-E1A 
interaction. This rules out the suggestion that NSC95397 mode of action could be by 
it acting as a CtBP1 substrate. NSC95397 reversed the repression of E-cadherin 
promoter (in H1299 small cell lung carcinoma cells) by CtBP. It is a known inhibitor of 
cdc25 phosphatase activity and spliceosomal activity. Thus, in order for it to be a useful 
CtBP inhibitor, potency and specificity has to be improved.  
The possible mechanism of action of this compound is that it might be locking CtBP1 
in a conformation which prevents it from binding to transcriptional factors, or it could 
be binding to the surface groove on CtBP at the conserved binding motif PXDLS, 
thereby directly inhibiting interaction of CtBP with transcriptional factors.  
 Figure 1-8. Structure of 
NSC95397 
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1.9. Scope of this dissertation 
This first project in my dissertation focuses on design and development of small 
molecule inhibitors that target CtBP for use as anti-cancer therapeutics. We have used 
a blend of classic traditional medicinal chemistry as well as modern computational 
techniques to approach the lead compounds. We succeeded in obtaining two 
compounds that are slightly more active in inhibiting CtBP and growth of cancer cells 
compared to the reported lead compound HIPP. These two compounds were found to 
be stable oximes, and did not have any off-target toxicity issues as determined by their 
lack of activity against LDH, a closely related enzyme of CtBP. 
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2. Structure-Guided Design of CtBP Inhibitors 
2.1. MTOB as an Inhibitor of CtBP  
MTOB (2-1), a putative substrate of CtBP shows bi-phasic kinetics – it acts as a 
substrate at lower concentrations, but acts as an inhibitor at higher concentrations. It 
has been shown to interfere with the oncogenic activity of CtBP in cells and mice.114 
MTOB displaced CtBP from the Bik promoter and thereby induced apoptosis in HCT-
116 colon cancer cells.83 In a mouse xenograft model, MTOB treated mice showed 
prolonged survival and less tumor burden compared to non-treated mice. MTOB 
shifted phenotypic indicators such as E-cadherin from mesenchymal to epithelial 
phenotype.70  
MTOB has provided a direction to develop small molecule inhibitors of CtBP (Figure 
2-1). Hilbert et al have reported the crystal structures of human CtBP1 (28-253) and 
CtBP2 (33-364) complexed with NAD(H) and ligand MTOB at 2.38 Å and 2.86 Å 
resolution respectively.114 
  
 
 
 
Above figure reprinted from “Crystal structures of human CtBP in complex with substrate MTOB reveal active site features 
useful for inhibitor design,” Brendan J. Hilbert, Steven R. Grossman, Celia A. Schiffer, and William E. Royer Jr.  FEBS Lett. 
2014, 588 (9), 1743-1748 Copyright 2014, with permission from Elsevier. 
 Figure 2-1. Crystal structure of CtBP1 in complex with MTOB 
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MTOB binds in the active site cleft between the coenzyme binding domain (125-319) 
and the substrate binding domain (28-120, 327-353). MTOB does not cause any 
tertiary or quarternary changes in the protein conformation upon binding. So, the 
mechanism of CtBP inhibition by MTOB could be through the substrate turnover → 
NAD+ generation and release → dimer dissociation → transcriptional regulation. Or, 
high MTOB concentrations (via substrate inhibition) → inhibit NADH to NAD+ 
conversion → inhibit monomer-dimer cycling → transcriptional regulation. 
Using the CtBP1(28-353)/MTOB/NAD+ crystal structure (Figure 2-2) as a starting 
point, we wished to design, synthesize, and evaluate small molecules that would inhibit 
the dehydrogenase activity of CtBP.  
The interactions between MTOB and CtBP1 in the binding site show sulphur-pi 
interactions between ‘S’ of MTOB and tryptophan 318 of CtBP (4 Å distance between 
the two). This Trp has been shown to function as a dimerization switch in CtBP1.115  
Arg97
MTOB
Arg266
NAD+
His315
Trp318
 
Figure 2-2. Interactions of MTOB with CtBP active site 
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Hydrogen-bonding interactions are observed between the carbonyl group of MTOB 
and Arg266, His315 of CtBP; between carboxylic acid portion of MTOB and Arg97, 
Arg266 of CtBP. The carbonyl is properly oriented towards His315 for hydride transfer. 
The backbone amides in substrate-binding domain also provide two hydrogen bonding 
interactions with MTOB.  
There is a hydrophilic cavity between MTOB binding site and NAD+. This cavity has 
four water molecules – W1, W2, W3 and W4 which link MTOB with the phosphate of 
NAD+ through hydrogen bonding (Figure 2-3). The conformation of A123 (hinge 
residue) is responsible for the presence of the cavity that holds water molecules.  
This cavity is absent in other D2-HDH enzymes because of large side chains which fill 
this volume and stabilize the substrates. 
Above figure reprinted with permission from “Structure-Guided Design of a High Affinity Inhibitor to Human CtBP,” Brendan J. 
Hilbert, Benjamin L. Morris, Keith C. Ellis, Janet L. Paulsen, Celia A. Schiffer, Steven R. Grossman, and William E. Royer, Jr.  
ACS Chem. Biol. 2015, 10, 1118-1127. Copyright 2015 American Chemical Society. 
 
Two features seen in the CtBP cocrystal structure that are not shared by other D2-
HDH enzymes are: conserved Trp (contributing to substrate specificity) and 
hydrophilic cavity (linking MTOB with phosphate of NAD+).  These features could be 
used to develop highly selective CtBP inhibitors.  
 Figure 2-3. Water network in MTOB-CtBP crystal structure 
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2.2. Design of CtBP Inhibitors Based on MTOB 
Based on the interactions observed in the crystal structure of CtBP1(28-
353)/MTOB/NAD+, it was hypothesized that increasing the pi-interactions with CtBP 
Trp318 might result in a potent inhibitor. Replacing the sulfur of MTOB with a 
methylene group decreased the enzymatic activity by 8-fold.106 This showed that pi-
interaction is important for activity. Thus, the first step was to increase the pi-
interactions of MTOB. We replaced the sulfur in MTOB (2-1, IC50 = 300 μM), with a 
phenyl ring to increase the π-interactions with Trp318 of CtBP (Scheme 2-1) giving 
rise to phenylpyruvic acid 2-2 (PPA). Hilbert et al arrived at this compound 
computationally through the Schrodinger Suite Glide program. Phenylpyruvic acid (2-
2) was tested in an NADH consumption assay, and was found to inhibit the reduction 
reaction of MTOB to MTHB by CtBP. Phenylpyruvic acid (2-2) was found to have an 
IC50 of 116 μM, which is about ~3-fold better inhibitor activity than MTOB (Table 2-1). 
Hilbert et al reported the crystal structure of PPA complexed with CtBP1 and NAD+ at 
2.1 Å resolution.116 The crystal structure of CtBP1 complexed with NAD+ and 
phenylpyruvic acid shows similar interactions as that of MTOB, and does not induce 
major conformational changes. The phenyl group makes pi-stacking interactions with 
Trp318. One interesting feature is that PPA assumes two different and proportionally  
 
Figure 2-4. Substrate conformation (yellow Coulombic) 
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equal conformations in the crystal structure (substrate and non-canonical). The 
substrate conformation (Figure 2-4) is similar to that of MTOB, where the carbonyl of 
PPA interacts through H-bonding with His315 and Arg266; and is oriented for hydride 
transfer from His315. In contrast, in the non-canonical conformation (Figure 2-5), the 
carboxylic acid group is oriented towards His315 and Arg266; and the carbonyl group 
is oriented towards Ser100 and away from His315, so is not positioned for hydride 
transfer. The binding affinities (energies) of both the conformations are not 
substantially different. 
 
Above figures 2-4 and 2-5 are reprinted with permission from “Structure-Guided Design of a High Affinity Inhibitor to Human 
CtBP,” Brendan J. Hilbert, Benjamin L. Morris, Keith C. Ellis, Janet L. Paulsen, Celia A. Schiffer, Steven R. Grossman, and 
William E. Royer, Jr.  ACS Chem. Biol. 2015, 10, 1118-1127. Copyright 2015 American Chemical Society. 
 
The water network is disrupted (different from that of MTOB, Figure 2-6). Because of  
a different conformation of A123, the cavity is collapsed, as a result of which the waters 
W2 and W3 are absent. In the substrate conformation, W1 (orange) is present; 
whereas W1 is absent in the non-canonical conformation. W4 is present similar to the 
position in the MTOB structure. 
 
 
 Figure 2-5. Non-canonical conformation 
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Above figure reprinted with permission from “Structure-Guided Design of a High Affinity Inhibitor to Human CtBP,” Brendan J. 
Hilbert, Benjamin L. Morris, Keith C. Ellis, Janet L. Paulsen, Celia A. Schiffer, Steven R. Grossman, and William E. Royer, Jr.  
ACS Chem. Biol. 2015, 10, 1118-1127. Copyright 2015 American Chemical Society. 
 
 
 
 
2.3. Structure-Activity Relationship (SAR) Study  
We further investigated the SAR of phenylpyruvic acid by synthesizing and testing 
various analogues. 
2.3.1. Deconstruction analogues of phenylpyruvic acid 
Phenylpyruvic acid was deconstructed to investigate which structural features of the 
molecule are important for activity. Three analogues were designed (Scheme 2-1): an 
analogue in which phenyl ring was removed – pyruvate (2-3), an analogue in which 
ketone was removed – hydrocinnamic acid (2-4), and an analogue in which carboxylic 
acid group was removed – 1-phenylpropan-2-one (2-5). All of these compounds were 
less active than phenylpyruvic acid. 
 
 
Figure 2-6. Water network of phenylpyruvic acid-CtBP crystal structure 
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2.3.2. Linker length analogues of phenylpyruvic acid 
In order to investigate what effect the linker length has on the activity, compounds 2-
6 (phenylglyoxylic acid – methylene spacer between phenyl ring and α-ketoacid 
removed), 2-7 and 2-8 were designed. These compounds were also either 
synthesized or purchased and tested for their ability to inhibit CtBP. 2-6 was less active 
than phenylpyruvic acid (we were unable to synthesize 2-7 and 2-8). 
 
Scheme 2-1. Deconstruction Analogues 
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2.3.3. Non-reducible Ketone Isosteres of phenylpyruvic acid 
Though phenylpyruvic acid (2-2) inhibits the dehydrogenase activity of CtBP, it is a 
substrate for the enzyme. To improve inhibition of CtBP, as well as to further establish 
the SAR of phenylpyruvic acid, we hypothesized that stopping this chemical reduction 
of phenylpyruvic acid (2-2) would result in better inhibitors. Thus, we designed 
compounds based on the phenylpyruvic acid structure by replacing α–ketone with 
isosteres that cannot be reduced by NADH. 
The hypothesis was that, if CtBP is unable to reduce the compound, then the 
compound would remain bound to CtBP and the turnover of the enzyme would be 
greatly reduced, resulting in inhibition of the protein. The following analogues were 
designed and tested (Scheme 2-2): ketone replaced by a sulfur – α-thioketone 2-9, 
ketone replaced by a methylene – acrylic acid 2-10, ketone replaced by a carboxylic 
acid – malonic acid 2-11, amide 2-12, ketone replaced by a hydrazine – hydrazone 2-
13, ketone replaced by an oxime – hydroxyimine (HIPP) 2-14. 
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Scheme 2-2. Non-reducible ketone isosteres of phenylpyruvic acid 
           
All of these compounds were either synthesized or purchased and tested for their 
ability to inhibit CtBP. Although most of these compounds were less active than 
phenylpyruvic acid (Table 2-1), the compound hydroxyimine 2-14 inhibited CtBP with 
an IC50 of 0.24 μM, a ~480-fold improvement over PPA (2-2). Hydroxyimine 2-14 was 
therefore chosen for further structure-activity relationship studies.  
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 Table 2-1. IC50 values of deconstruction analogues and PPA ketone isosteres 
Compound 
IC50 (μM)a 
MTOB (2-1) 300 
2-2 116.3 
2-3 >300 
2-4 >300 
2-5 >300 
2-6 >300 
2-9 >300 
2-10 >300 
2-11 >300 
2-12 >300 
2-13 >300 
2-14 0.24 
 
2.3.4. SAR of the Lead Compound HIPP 
With the above results, which helped us understand the minimum structural elements 
needed to inhibit CtBP, we designed a large set of analogues based on the best 
inhibitor in our series – hydroxyimine 2-14. In the next series, we worked on exploring 
the structure-activity relationship of the phenyl ring. Our set of analogues included 
electronically and sterically diverse substituents. All analogues were evaluated 
computationally by docking them into the site identified in the CtBP-2-14 crystal 
structure to prioritize synthesis and evaluation. Docking scores were calculated with 
the HINT scoring function;117 this identified thirteen compounds 2-15 through 2-27 
that we selected for synthesis and evaluation as inhibitors of CtBP (Figure 2-7). 
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Figure 2-7. Oximes selected for synthesis 
 
All these compounds were tested against recombinant CtBP and in HCT-116 cells. 
Compounds 2-21 and 2-22 were found to be the most potent analogues in this series 
based on the lead compound 2-14 (Table 2-2). 
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             Table 2-2. IC50 values of oxime analogues 
Compound Substituent CtBP IC50 (μM)a Cellular IC50 (mM)a 
2-14 
H 
0.24 (0.21, 0.27) 4.12 (2.96, 5.73) 
2-15 4-Me 0.32 (0.29, 0.37) 3.28 (2.51, 4.28) 
2-16 3-Me 0.48 (0.43, 0.54) 3.26 (2.71, 3.93) 
2-17 2-Me 8.73 (6.19, 12.29) 0.23 (0.16, 0.35) 
2-18 4-OMe 2.16 (1.19, 3.90) 1.93 (1.65, 2.25) 
2-19 3-OMe 0.88 (0.81, 0.97) 5.60 (3.56, 8.84) 
2-20 2-OMe > 100 1.24 (1.02, 1.51) 
2-21 4-Cl 0.18 (0.16, 0.20) 1.74 (1.47, 2.06) 
2-22 3-Cl 0.17 (0.15, 0.19) 0.85 (0.76, 0.96) 
2-23 2-Cl 7.65 (5.93, 9.86) 2.37 (1.83, 3.08) 
2-24 4-OH 7.34 (5.26, 10.25) >10 
2-25 3-OH 0.72 (0.67, 0.78) >10 
2-26 4-F 0.30 (0.27, 0.33) 
3.97 (3.52, 4.49) 
2-27 4-CN 0.90 (0.82, 0.98) 1.10 (0.81, 1.49) 
MTOB (2-1) --- n.d. 4.0 
 
2.3.5. Second generation analogues 
Based on the above results, we synthesized second generation analogues (Figure 2-
8). As the compounds 2-21 (4-Cl HIPP) and 2-22 (3-Cl HIPP) had very good activity, 
the next obvious compound to synthesize was 3, 4-dichloro HIPP (2-28) to see if 
incorporation of chloro groups at both the positions would give a better inhibitor. We 
also synthesized 2,4-dichloro HIPP (2-29) to see if there would be any improvement 
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in the activity. The next compound we synthesized was 4-trifluromethyl HIPP (2-30) to 
investigate if a more electron withdrawing group in the para position would improve 
the activity relative to 4-Cl HIPP (2-21). 
         
 
 
 
 
 
In parallel with this study to explore the structure-activity relationship of hydroxyimine 
2-14, our collaborators co-crystallized 2-14 with CtBP1 and NADH at a resolution of 
2.3 Å (Figure 2-9).118 It assumes the non-canonical conformation, i.e. the oxime group 
is oriented away from His315, so hydride transfer cannot occur. If this compound were 
to adopt a substrate conformation (i.e. oxime oriented towards His315), then a large 
conformational change in the protein would be necessary to prevent oxime from 
clashing with His315. The carboxylic acid group forms H-bonds with His315 and 
Arg266, Coulombic interactions with Arg97. The oxime forms H-bond with Ser100. It 
also forms a H-bond with an active site water molecule, which stabilizes it.  
 
Figure 2-8. Second generation analogues 
Figure 2-9. CtBP1-NADH-HIPP crystal structure 
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Above figure reprinted with permission from “Structure-Guided Design of a High Affinity Inhibitor to Human CtBP,” Brendan J. 
Hilbert, Benjamin L. Morris, Keith C. Ellis, Janet L. Paulsen, Celia A. Schiffer, Steven R. Grossman, and William E. Royer, Jr.  
ACS Chem. Biol. 2015, 10, 1118-1127. Copyright 2015 American Chemical Society. 
 
The phenyl ring forms pi-stacking interactions with Trp318 (Figure 2-10, from PyMol). 
This van der Waals interaction is 2-3 fold greater than the sulfur-pi interaction in 
MTOB.  
 
The water network is different from that of MTOB. W1 is displaced completely by the 
hydroxyl group of the oxime. Both W2 and W3 have shifted. HIPP interacts directly 
with W2. The positions of W2 and W3 clash (1.9 Å apart). There is no change in the 
position of W4 (Figure 2-11). 
 
 
 
Figure 2-10. Interactions of HIPP at CtBP active site 
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Above figure reprinted with permission from “Structure-Guided Design of a High Affinity Inhibitor to Human CtBP,” Brendan J. 
Hilbert, Benjamin L. Morris, Keith C. Ellis, Janet L. Paulsen, Celia A. Schiffer, Steven R. Grossman, and William E. Royer, Jr.  
ACS Chem. Biol. 2015, 10, 1118-1127. Copyright 2015 American Chemical Society. 
 
HIPP (Kd = 0.37 µM) has been shown to bind to CtBP1 with 1000-fold more affinity 
than that of MTOB (Kd = 1.26 mM) through Isothermal Titration Calorimetry (ITC) 
experiment. Though HIPP is expected to show competitive inhibition (no change in 
Vmax, but increase in Km) due to its binding in the substrate binding site, kinetic 
experiments indicate non-competitive inhibition (decrease in Vmax, but no change in 
Km). This could be because NADH binding causes a conformational change in the 
protein leading to domain closure, which prevents release of NAD+ after product 
(MTHB) release, and permits binding of a molecule of inhibitor (HIPP) or substrate 
(MTOB). This forms an abortive ternary complex resulting in enzyme non-competitive 
inhibition by HIPP. This model has not been completely investigated yet.  
Figure 2-11. Water network of HIPP at the binding site 
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2.4. Syntheses and Biological Assays of CtBP Inhibitors 
2.4.1. Syntheses of the compounds 
The compounds MTOB (2-1), phenylpyruvic acid (2-2), pyruvic acid (2-3), 
hydrocinnamic acid (2-4), phenylglyoxylic acid (2-6), 2-benzylacrylic acid (2-10), 
benzylmalonic acid (2-11) and anilino(oxo)acetic acid (2-12) were purchased from 
commercial sources. 
The compound 2-5 was synthesized by reacting phenylacetic acid (3-1) with 
dimethylhydroxylamine hydrochloride under EDC coupling conditions to give the 
Weinreb amide 3-2. This underwent Grignard reaction with methylmagnesium bromide 
under anhydrous conditions to furnish the product 2-5 (Scheme 2-3).  
The compound 2-9 was synthesized by the reaction of benzaldehyde (3-3) and 
rhodanine (3-4) to give the condensed intermediate benzalrhodanine (3-5), which 
underwent hydrolysis under basic conditions to furnish the thioketone product 2-9 
(Scheme 2-4). 
 
 
Scheme 2-3. Synthesis of compound 2-5 
Scheme 2-4. Synthesis of compound 2-9 
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The hydrazone 2-13 was synthesized by reacting phenylpyruvic acid (3-6) with 
hydrazine under basic conditions. The hydroxyimine compound 2-14 was synthesized 
by reacting phenylpyruvic acid (3-6) with hydroxylamine hydrochloride under basic 
conditions (Scheme 2-5). 
 
 
 
 
 
 
 
 
To synthesize the hydroxyimine analogues, we chose hydantoin chemistry as a 
general route that would offer the flexibility needed to introduce a variety of 
substituents on the phenyl ring (Scheme 2-6). Condensation of substituted 
benzaldehydes (3-7a through 3-17a) with hydantoin under basic conditions afforded 
the 5-benzylideneimidazolidine-2,4-diones (3-7b through 3-17b), which were then 
hydrolyzed to afford a variety of substituted phenylpyruvic acid analogues (3-7c 
through 3-17c). These phenylpyruvic acid analogues were then condensed with 
hydroxylamine to form the hydroxyimine analogues (2-15 through 2-27). We found this 
synthetic route to be highly tolerant of substitutions on the starting benzaldehyde and 
were able to synthesize eleven of the thirteen analogues using this methodology.  
 Scheme 2-5. Synthesis of compound 2-14 
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For the two compounds (2-19 and 2-22) where condensation of the benzaldehyde with 
the hydantoin failed to afford the 5-benzylideneimidazolidine-2,4-dione, we used the 
alternative methodology shown in (Scheme 2-7).  
 
 
 
 
Scheme 2-6. Synthesis of α-keto-acids and oximes from hydantoin 
Scheme 2-7. Synthesis of α-keto-acids and oximes from 1,4-diacetylpiperazine-2,5-dione 
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This alternative method utilized a condensation of benzaldehydes 3-18a and 3-19a 
with 1,4-diacetylpiperazine-2,5-dione to afford the 1-acetyl-3-benzylidenepiperazine-
2,5-diones 3-18b and 3-19b. These intermediates were then hydrolyzed to afford the 
phenylpyruvic acid analogues 3-18c and 3-19c, followed by condensation with 
hydroxylamine to form the hydroxyimine analogues 2-19 and 2-22. We were unable to 
synthesize compounds 2-7 and 2-8.  
 
Second generation analogues 
 
For the three compounds (2-28, 2-29 and 2-30), where condensation of the 
benzaldehyde with both hydantoin and 1,4-diacetylpiperazine-2,5-dione failed to 
afford the corresponding condensed intermediates, we used the alternative 
methodology shown in (Scheme 2-8). This alternative method utilized a condensation 
of benzaldehydes 3-20a, 3-21a and 3-22a with N-acetylglycine to afford the 
condensed intermediates 3-20b, 3-21b and 3-22b. These intermediates were then 
hydrolyzed to afford the phenylpyruvic acid analogues 3-20c, 3-21c and 3-22c, 
followed by condensation with hydroxylamine to form the hydroxyimine analogues 2-
28, 2-29 and 2-30. 
 Scheme 2-8. Synthesis of second generation analogues 
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2.4.2. Biological Assays – Recombinant CtBP and Cellular assays 
All the compounds synthesized above or purchased were tested against recombinant 
CtBP enzyme and also in cellular growth/viability assays (HCT-116 p53-/- colon cancer 
cells). While most of the compounds were inactive, three compounds 2-14, 2-21 and 
2-22 showed good inhibitory activity against CtBP. 
2.4.3 LDH Assay to Determine Off-target Toxicity 
Lactate Dehydrogenase is closely related to CtBP in structure and function. We wished to test 
if our compounds are specific against CtBP. Thus, three compounds (most potent in our 
series) – HIPP, 3-Cl HIPP and 4-Cl HIPP were tested for their ability to inhibit L-Lactate 
Dehydrogenase (LDH from rabbit muscle). Sodium oxamate (a known inhibitor of LDH) was 
used as the standard. Stock solutions of the compounds in DMSO were added to a reaction 
mixture containing phosphate buffer (pH 7.2), LDH, pyruvate and NADH. The enzyme 
inhibition was measured by monitoring change in levels of NADH (absorbance) over a period 
of 30 min. The minimal concentration of compounds leading to 50% inhibition of LDH activity 
(IC50) was calculated using non-linear regression of the experimental data, using Prism 
software (GraphPad).  
The average IC50 (µM) values are reported below: 
Compound IC50 (µM) 
HIPP 42.53 ± 0.11 
3-Cl-HIPP 94.86 ± 7.51 
4-Cl-HIPP 181.9 ± 12.87 
oxamate 45.80 ± 1.89 
 
Detailed experimental procedure is reported in 6.4d. 
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2.4.4. HPLC Study to Determine Stability of the Oxime Compounds 
As the in vitro activity and the in vivo activity of the oxime compounds did not show 
proper correlation, we wanted to test if the oxime compounds are unstable under the 
assay conditions, as instability of the compounds would explain the complex SAR 
between in vitro and in vivo activities. We tested the stability of three most potent 
(HIPP, 3-Cl HIPP and 4-Cl HIPP) compounds by HPLC. These compounds were found 
to be stable.  
 
2.5. Discussion 
2.5.1. Inhibitory activity against Recombinant CtBP 
Starting from MTOB (2-1, IC50 = 300 μM), phenylpyruvic acid (2-2) was found to be a 
~3-fold better inhibitor than MTOB (Table 2-1) with an IC50 of 116 μM. Compounds 2-
3, 2-4, 2-5 and 2-6 were less active than phenylpyruvic acid (we were unable to 
synthesize compounds 2-7 and 2-8). Compounds 2-9 through 2-13 were less active 
than phenylpyruvic acid itself (Table 2-1), whereas hydroxyimine 2-14 inhibited CtBP 
with an IC50 of 0.24 μM, a ~480-fold improvement over PPA.  
Hydroxyimine analogues 2-15 through 2-27 were tested for their ability to inhibit the 
functional dehydrogenase activity of CtBP in a NADH disappearance assay. Relative 
to the parent hydroxylamine 2-14, we observed that ortho-substitutions on the ring 
were detrimental to inhibitory activity [2-17 (2-Me), 2-20 (2-OMe), 2-23 (2-Cl), Table 2-
2]. Para- and meta-substitution by electron-donating groups [2-18 (4-OMe), 2-19 (3-
OMe), 2-24 (4-OH), 2-25 (3-OH)] resulted in a large decrease (4-OH) or a small 
decrease (4-OMe, 3-OMe, 3-OH) in inhibitory activity. Para- and meta-substitution by 
the electronically neutral methyl group [2-15 (4-Me), 2-16 (3-Me)] resulted in only a 
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small decrease in inhibitory activity. However, para- and meta-substitution by an 
electron-withdrawing chlorine group [2-21 (4-Cl), 2-22 (3-Cl)] resulted in analogues 
that were more active as inhibitors than parent hydroxyimine 2-9. Interestingly, this 
effect seems specific to chlorine as para- substitutions with other electron-withdrawing 
groups [2-26 (4-F), 2-27 (4-CN)] resulted in no increase in inhibition (2-26) or a 
decrease in inhibitory activity (2-27).  
We are yet to test the activity of our second generation analogues. 
2.5.2. Inhibitory activity against Cellular CtBP (HCT-116 Colon Cancer Cells) 
To determine whether inhibition of the dehydrogenase activity of CtBP by 
hydroxyimine 2-14 and analogues 2-15 through 2-27 is effective at inhibiting cancer 
cell growth, we carried out a short-term cell growth/viability assay (Table 2-2). HCT-
116 p53-/- colorectal cancer cells were treated with the compounds for 72 hours and 
cell growth and viability was determined by MTT assay. Compounds 2-17, 2-20, 2-21, 
2-22 and 2-27 were found to inhibit the growth of HCT-116 cells. 
2.5.3. SAR – In vitro vs In vivo Activity 
A complex structure/activity relationship was observed, between enzyme inhibition 
and cell inhibitory activity, shown by the plot in Figure 2-12. A number of compounds 
appeared to have cytotoxic effects out of proportion to their enzymatic activity, 
consistent with off-target toxicity 2-18 (4-OMe), 2-27 (4-CN), while others had lower 
than expected cellular inhibitory effects consistent with instability or poor intracellular 
penetration 2-19 (3-OMe), 2-25 (3-OH). However, a series of compounds exhibited a 
relatively consistent correlation of enzymatic and cellular inhibitory activity 2-15 (4-
Me), 2-16 (3-Me), 2-21 (4-Cl), 2-22 (3-Cl), 2-26 (4-F) with 2-21 (4-Cl) and 2-22 (3-Cl) 
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demonstrating the strongest enzymatic and cellular inhibitory activity of this subset of 
the compounds.  
 Figure 2-12. Enzymatic vs cellular activity of inhibitors 
 
2.5.4. Docking of Inhibitors in the Active Site of CtBP 
More detailed computational docking with this crystal structure model were performed 
to support the SAR studies.  While no clear trend in docking scores vs. protein or 
cellular inhibition IC50’s were found, the docked poses of designed analogues at CtBP 
active site revealed factors important for binding and inhibition. Most importantly, the 
phenyl rings of the ligands fit well in a hydrophobic region primarily formed by Try318, 
Tyr76 and Met327. Compounds 2-15 and 2-21 form stronger hydrophobic and aryl-X 
interactions in the pocket, compared to 2-24, where its polar (OH) substitution results 
in unfavorable hydrophobic-polar interactions. These results will inform our design of 
next-generation analogues. 
2.5.5. Off-target Toxicity 
The three most potent compounds in our series – HIPP, 3-Cl HIPP and 4-Cl HIPP 
showed no inhibition against LDH, a closely related enzyme to CtBP. This shows that 
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our inhibitors are highly specific for CtBP. The aryl ring (complementary to Trp318 of 
CtBP), and the α-keto acid portion of the molecule (in the hydrophilic cavity of CtBP) 
might be conferring selectivity towards CtBP vs other dehydrogenases which lack 
these two key features present in CtBP. So, the compounds 2-17, 2-18, 2-20, 2-23 
might be targeting some other proteins resulting in their cytotoxic effects (poor in vitro 
activity but good in vivo activity). 
2.5.6. Stability of Oximes 
As the in vitro activity and the in vivo activity of the oxime compounds did not show 
proper correlation, we wanted to test if the oxime compounds are indeed stable under 
the assay conditions, as instability of the compounds would explain the complex SAR 
between in vitro and in vivo activities. We tested the stability of three most potent 
(HIPP, 3-Cl HIPP and 4-Cl HIPP) compounds by HPLC (detailed procedure in section 
2.7.8). These compounds were found to be stable. Thus, it is highly possible that 
compounds 2-19 and 2-25 might be having cell permeability issues (good in vitro 
activity but poor in vivo activity). 
2.5.7. Hypothesis and Model  
There is concrete evidence in the literature that targeting CtBP could be a highly tumor-
selective and effective strategy for treating cancer. CtBP is activated as a 
transcriptional co-regulator only under conditions that are unique to tumor cells 
(hypoxia and/or high NADH concentration – Warburg effect). Disrupting the 
transcriptional co-regulatory function of CtBP in a tumorigenic environment has wide 
ranging effects on multiple cellular mechanisms, as was seen in the genomic study by 
Gardner and coworkers,70 and can restore the natural, endogenous function of tumor 
suppressor genes.  
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While genetic inhibition of CtBP (with siRNA) and pharmacological inhibition with 
peptides are effective tools for studying the role of CtBP in cancer biology, small 
molecule inhibitors of CtBP are needed for further clinical drug development. Here we 
report the first small molecule inhibitors for CtBP, and have optimized inhibition of the 
dehydrogenase function of CtBP to a submicromolar level.  
While these compounds are effective inhibitors of recombinant CtBP, high 
concentrations are still required to inhibit growth in cells, with the in vivo cell growth 
inhibitory activity of the best compounds disappointingly falling at just below 1 mM. 
Earlier work with the parent compound MTOB, however, suggests that in long term 
colony formation assays, GI50 values are usually 10-fold lower than those seen in short 
term assays, and those studies are ongoing with the hydroxyimine derivatives.  
 
Even taking the possible 10-fold lower GI50 of CtBP inhibitors in long-term assays into 
account, the cellular inhibitory constants for the current series of CtBP inhibitors 
remain 2-3 orders of magnitude higher than the in vitro IC50’s.  A possible rationale for 
this effect is that in cancer cells, CtBP has already formed transcriptional co-repression 
complexes with NADH, transcription factors, and repressor enzymes, and is not 
available for effective inhibitor binding. Binding of the inhibitor to CtBP either must 
break up the transcriptional co-repression complex or wait until the complex 
dissociates naturally in order to bind. This mechanistic model is consistent with our 
data that the compounds effectively bind to and inhibit the dimeric form of CtBP 
generated in the in vitro assay. We are currently working to investigate this 
mechanistic model and develop analogues with improved activity in the cellular 
assays. We are also using these new CtBP inhibitors as tools for studying the role of 
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CtBP in cell survival and migration, as well as the impact of restoring tumor suppressor 
gene expression and inhibiting oncogenes in tumor cells.  
 
2.6. Computational Approach towards Design of Diverse CtBP Inhibitors 
Arriving at lead compounds quickly and efficiently (both time and cost-wise) is best 
achieved by using a combination of different approaches. We used computational 
approaches to design more CtBP inhibitors complementary to the traditional medicinal 
chemistry SAR approach discussed above. Through computational approaches, a 
large chemical space can be explored and diverse scaffolds of lead compounds could 
be identified in less time, which is not always possible with the traditional medicinal 
chemistry approach.  
Virtual screening is a computational process in which a large set of compound 
libraries can be screened to identify compounds that could potentially bind in a 
particular proteins binding site. It is a process in which we can virtually filter 
compounds that need to be synthesized/purchased and tested, thereby saving on the 
time and resources. It can either be ligand-based or structure-based. In ligand-based 
virtual screening, the features of a pharmacophore (from a known ligand of a protein) 
are used to screen libraries of compounds. In structure-based virtual screening, 
compounds are docked into the active site of the protein, and scored using scoring 
functions to determine which compounds are likely to bind to the protein. 
We carried out virtual screening of the ZINC database using UNITY in SYBYL using a 
combination of both ligand-based and structure-based methods. We utilised the co-
crystal structure of CtBP-NADH-HIPP. The binding pocket with HIPP is shown in the 
figure below (Figure 2-13).  
UNITY query features: We defined the following features as queries in UNITY.  
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a. Aromatic feature – 1.5 Å radius – complementary to Trp318 (pi-stacking) 
b. Aromatic feature – 1.0 Å radius – complementary to Tyr76 (pi-stacking) 
c. Negative center – 1.0 Å radius – complementary to Arg266 (electrostatic) 
d. Acceptor site – 1.0 Å radius – at His 315 (H-bond) 
e. Exclusion spheres – 0.75 Å radius – receptor cavity (to avoid clashes) 
f. Bond path constraint – 3-5 bonds – between negative center and aromatic 
feature. 
We performed a UNITY Flex search to screen the ZINC database of clean drug-like 
subset (~10 million compounds). We obtained 289 hits. 
 Docking is a process in which the compounds are docked in the binding site of a 
protein to see which conformations the compound can possibly bind in. We performed 
docking of the 289 hits using GOLD. The binding cavity was defined as 10 Å radius 
around Arg266, the number of GA runs was 50. 
Scoring is a process in which the different docked poses are ranked based on the 
favorable and unfavorable interactions. Higher score means more favourable 
Trp318
NAD+
Tyr76
His315
Arg266
Arg97
*Aromatic
*Aromatic
*Negative center
*Acceptor site
 
Figure 2-13. UNITY features based on HIPP 
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interactions usually, although the poses have to be manually visualized to make sure 
that the interactions are possible, and are not errors. We used HINT scoring function 
to score all the solutions obtained from GOLD. Initial top HINT scores of best ligand 
conformations 1290-1926. We then performed energy minimization of top scored 50 
protein-ligand complexes (to mimic actual binding of compound to the protein) followed 
by HINT rescoring of ligands. The final HINT scores were around 1362-2294.  
We evaluated binding modes of these compounds, an example (ZINC 02586210, final 
HINT score 2294) is shown below (Figure 2-14). There are two phenyl rings (yellow) 
which show pi-stacking interactions with Tyr76 and Trp318. The carboxylate group 
(red) shows electrostatic interactions with Arg266 and Arg97. The amine (blue) has a 
H-bonding interaction with His315.  
 
Based on the HINT scores, we ordered the following 10 hits, and are yet to test their 
activity against CtBP (Figure 2-15).  
Arg266
Arg97
Trp318
Tyr76
His315
Figure 2-14. Binding mode of compound ZINC02586210 
 50 
 
 
 
 
 
 
 
 
 
 
 
Figure 2-15. Hits obtained through virtual screening to be tested 
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2.7. Experimental Procedures 
 
2.7.1. General Chemical Methods 
Reagents/chemicals, catalysts, solvents were purchased from Sigma-Aldrich, Fisher 
and Alfa-Aesar. Analytical Thin Layer Chromatography (TLC) was performed using 
silica gel GHLF plates (Analtech Inc.). Flash chromatography was performed on 
TELEDYNE ISCO CombiFlash® Rf instrument using RediSep Rf Normal-phase Flash 
Columns (4-gm, 12-gm, 24-gm or 40-gm).  1H NMR and 13C NMR experiments were 
recorded on BRUKER 400MHz NMR instrument in deuterated solvents - chloroform 
(CDCl3), acetone ((CD3)2CO), dimethyl sulfoxide ((CD3)2SO) or methanol (CD3OD). All 
chemical shifts are reported in parts per million (ppm) with reference to chloroform, 
acetone, DMSO and methanol residual peaks at 7.26, 2.05, 2.50 and 3.31 respectively 
(1H NMR spectra); 77.16, 29.84, 39.52 and 49.00 respectively (13C NMR spectra).  The 
data is reported as: chemical shifts (ppm), multiplicity (s = singlet, d = doublet, t = 
triplet, m = multiplet), coupling constant(s) (Hz) and integral values. 
 
2.7.2. Rationally Designed and Deconstruction Analogues 
The following compounds were purchased from commercial sources and tested for 
CtBP inhibition without further purification: 4-methylthio-2-oxobutyric acid (MTOB, 2-
1, Sigma-Aldrich), phenyl pyruvic acid (2-2, Sigma-Aldrich), 2-benzylacrylic acid (2-10, 
TCI America), benzylmalonic acid (2-11, Sigma Aldrich), anilino(oxo)acetic acid (2-12, 
Sigma-Aldrich), pyruvate (2-3, Sigma-Aldrich), hydrocinnamic acid (2-4, Sigma 
Aldrich), and phenylglyoxylic acid (2-6, Sigma-Aldrich). 
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3-Phenyl-2-thioxopropanoic acid (2-9). Rhodanine 3-4 (1.25 g, 9.4 mmol), anhydrous 
sodium acetate (2.16 g, 26.4 mmol), and benzaldehyde 3-3 (1.0 g, 9.4 mmol) were 
added to a vial followed by glacial acetic acid (17.8 mL, 0.53 M). The reaction was 
heated to 115 °C for three hours, upon which time the reaction had turned orange and 
developed a precipitate.  The reaction mixture was cooled to room temperature and 
poured into ice water, which caused additional precipitate to form. Upon warming to 
room temperature, the precipitate was filtered and then dried in a oven for 36 hours to 
afford a dry powder 3-5 (1.66 g, 80% yield). This intermediate was dissolved in water 
(10 mL) and 6N sodium hydroxide (10 mL) and heated to 95 °C for 1 h. The reaction 
mixture was cooled to room temperature, water (10 mL) was added, and 6N HCl was 
added to crash out a white precipitate. This precipitate was filtered and purified by 
flash chromatography (silica gel, 5% MeOH/DCM) to afford the product (0.86 g, 63% 
yield). 1H NMR (400 MHz, (CD3)2SO) δ 7.74 (s, 1H), 7.68 (d, J = 7.4 Hz, 2H), 7.48 (t, 
2H), 7.42-7.36 (m, 1H). HRMS C9H7O2S [M-H]- Expected: 179.0167, Found: 179.0164. 
 
 
2-hydrazono-3-phenylpropanoic acid (2-13): Phenylpyruvic acid 3-6 (0.1 g, 0.61 mmol) 
is dissolved in ethanol (0.4 ml). Hydrazine (0.02 mL, 0.61 mmol) is added and the 
reaction mixture is stirred overnight at room temperature. Sodium carbonate (0.03 g, 
0.31 mmol) is added and the reaction mixture is stirred for 2 h at room temperature. 
The precipitated solid is filtered and dried to give the title compound in 62% yield (0.07 
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g, 0.38 mmol). 1H NMR (400 MHz, DMSO) δ 7.26 (d, J = 7.5 Hz, 2H), 7.19 (t, J = 7.7 
Hz, 2H), 7.10 (t, J = 7.5 Hz, 1H), 6.26 (s, 2H), 3.78 (s, 2H); 13C NMR (125 MHz, DMSO) 
δ 168.60, 146.52, 138.01, 128.68, 127.88, 125.37, 30.21. HRMS C9H10N2O2 [M+Na]- 
Expected: 201.0634, Found: 201.0622. 
 
 
2-(hydroxyimino)-3-phenylpropanoic acid (2-14): Phenyl pyruvic acid 3-6 (3.0 g, 18.28 
mmol) was dissolved in a solution of NaOH (2.2 g, 54.83 mmol) in water (1 mL).  
Hydroxylamine hydrochloride (1.9 g, 27.41 mmol) was added to the reaction and 
stirred overnight at room temperature. 1N HCl was added to the reaction, the 
precipitated product is filtered and dried. The crude product is purified using flash 
chromatography (silica gel, 5% MeOH/DCM). Yield: 76% (2.50 g, 13.95 mmol). 1H 
NMR (400 MHz, DMSO) δ 12.28 (s, 1H), 7.27 (m, 2H), 7.19 (m, 3H), 3.82 (s, 2H); 13C 
NMR (125 MHz, DMSO) δ 165.14, 150.13, 136.68, 128.52, 128.32, 126.13, 29.85. 
HRMS C9H9NO3 [M-H]- Expected: 178.0509, Found: 178.0494. 
 
 
1-phenylpropan-2-one (2-5): Phenylacetic acid 3-1 (0.5 g, 3.7 mmol) was dissolved in 
DCM (9.2 mL). To this, N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride 
(0.8 g, 4.4 mmol), 4-methylmorpholine (0.4 g, 3.7 mmol), N,O-Dimethylhydroxylamine 
hydrochloride (0.4 g, 4.0 mmol) were added. The reaction mixture was stirred at room 
temperature for 4 h. It was concentrated and diethyl ether was added. The organic 
layer was washed with brine, dried over Na2SO4 and evaporated. Purification of the 
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residue on silica gel (5:1 hexanes/EtOAc) afforded the product N-methoxy-N-methyl-
2-phenylacetamide 3-2 in 87% yield. 0.6 g (3.2 mmol) of this product was dissolved in 
ether (10.6 ml) under nitrogen at 0 oC. Methylmagnesium bromide solution (3.4 mL, 
4.8 mmol, 1.4 M in THF:toluene 1:3) was added over 30 min. The reaction was stirred 
at 0 oC for 1 h and at room temperature for 30 min. It was quenched at 0 oC with the 
slow addition of 1 M HCl. The reaction was extracted with ether. The organic layer was 
washed with brine, dried over Na2SO4 and evaporated. Purification of the residue on 
silica gel (5:1 hexanes/EtOAc) afforded the product 1-phenylpropan-2-one in 89% 
yield (0.38 g, 2.83 mmol). 1H NMR (400 MHz, MeOD) δ 7.21-7.33 (m, 5H), 3.75 (s, 
2H), 2.15 (s, 3H); 13C NMR (125 MHz, MeOD) δ 209.24, 136.00, 130.58, 129.67, 
127.97, 51.37, 29.27. HRMS C9H10O [M-H]- Expected: 133.0659, Found: 132.0813. 
2.7.3. Synthesis of Hydroxyiminophenylpyruvic acid Analogues 
2.7.3.1. Synthesis of keto-acid intermediates 
General Procedure 1: Hydantoin (15.0 mmol) was dissolved in water (15.0 mL) at 70 
oC. The pH of the solution was adjusted to 7 using saturated sodium bicarbonate 
solution. Ethanolamine (1.4 mL) was added and the temperature was raised to 90 oC. 
The corresponding aldehyde (15.0 mmol) in ethanol (15.0 mL) was added drop wise 
to the reaction mixture. The reaction was refluxed at 120 oC for 5-10 h. After being 
cooled to room temperature, the product was filtered, washed with alcohol/water (1:5) 
and dried to give the corresponding benzalhydantoin intermediate. This corresponding 
benzylhydantoin (8.98 mmol) was dissolved in 20% aqueous NaOH solution (28.4 mL) 
and refluxed at 100 oC for 3 h. After being cooled to room temperature, 12N HCl (11.8 
mL) was added. Sodium bicarbonate was added to bring the pH to 7. The reaction 
mixture was extracted with ether until the ether layer was clear. This layer was 
discarded. To the aqueous layer, 12N HCl (7.1 mL) was added. It was extracted with 
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ether until no more acid was obtained. The ether layer was dried to give the crude keto 
acid. It was recrystallized in water to give pure product.  
 
2-oxo-3-p-tolylpropanoic acid (3-7c): Procedure 1 was followed using 4-
methylbenzaldehyde. Yield 54% (1.0 g, 5.61 mmol). 1H NMR (400 MHz, MeOD) δ 
7.64-7.66 (d, J = 8.1 Hz, 2H), 7.12-7.14 (d, J = 8.1 Hz, 2H), 6.46 (s, 1H), 2.32 (s, 3H); 
13C NMR (125 MHz, MeOD) δ 168.46, 141.49, 138.44, 133.49, 130.72, 129.87, 
111.79, 21.28. HRMS C10H10O3 [M-H]- Expected: 177.0557, Found: 177.0562. 
 
2-oxo-3-m-tolylpropanoic acid (3-8c): Procedure 1 was followed using 3-
methylbenzaldehyde. Yield 57% (0.3 g, 1.68 mmol). 1H NMR (400 MHz, MeOD) δ 7.57 
(d, J = 4.1 Hz, 1H), 7.55 (s, 1H), 7.18-7.22 (t, J = 7.5 Hz, 1H), 7.03-7.05 (d, J = 7.9 Hz, 
1H), 6.45 (s, 1H), 2.32 (s, 3H); 13C NMR (125 MHz, MeOD) δ 170.0, 143.64, 140.38, 
137.85, 132.89, 130.72, 129.55, 113.34, 23.07. HRMS C10H10O3 [M-H]- Expected: 
177.0557, Found: 177.0565. 
 
2-oxo-3-o-tolylpropanoic acid (3-9c): Procedure 1 was followed using 2-
methylbenzaldehyde. Yield 58% (0.08 g, 0.45 mmol). 1H NMR (400 MHz, (CD3)2CO) 
δ 8.18 (d, J = 8.2 Hz, 1H), 7.85 (s, 1H), 7.11-7.23 (m, 4H), 6.74 (s, 1H), 2.38 (s, 3H); 
13C NMR (125 MHz, (CD3)2CO) δ 167.10, 141.15, 137.11, 133.96, 130.84, 130.64, 
 56 
 
128.34, 126.63, 107.60, 20.13. HRMS C10H10O3 [M-H]- Expected: 177.0557, Found: 
177.0549. 
 
 
3-(4-methoxyphenyl)-2-oxopropanoic acid (3-10c): Procedure 1 was followed using 4-
methoxybenzaldehyde. Yield 88% (1.8 g, 9.27 mmol). 1 H NMR (400 MHz, MeOD) δ 
7.71-7.73 (d, J = 8.8 Hz, 2H), 6.88-6.90 (d, J = 8.9 Hz, 2H), 6.46 (s, 1H), 3.80 (s, 3H); 
13C NMR (125 MHz, MeOD) δ 168.61, 160.57, 140.55, 132.24, 129.08, 114.76, 
111.83, 55.69. HRMS C10H10O4 [M-H]- Expected: 193.0506, Found: 193.0511. 
 
 
3-(2-methoxyphenyl)-2-oxopropanoic acid (3-11c): Procedure 1 was followed using 2-
methoxybenzaldehyde. Yield 56% (0.23 g, 1.29 mmol). 1H NMR (400 MHz, MeOD) δ 
8.20-8.22 (m, 1H), 7.19-7.23 (m, 1H), 6.90-6.95 (m, 3H), 3.86 (s, 3H); 13C NMR (125 
MHz, MeOD) δ 168.64, 158.20, 141.79, 131.72, 129.78, 124.98, 121.41, 111.46, 
105.03, 56.11. HRMS C10H10O4 [M-H]- Expected: 193.0506, Found: 193.0496. 
 
3-(4-chlorophenyl)-2-oxopropanoic acid (3-12c): Procedure 1 was followed using 4-
chlorobenzaldehyde. Yield 62% (1.1 g, 5.54 mmol). 1H NMR (400 MHz, MeOD) δ 7.74-
7.76 (d, J = 8.8 Hz, 2H), 7.30-7.32 (d, J = 8.5 Hz, 2H), 6.45 (s, 1H); 13C NMR (125 
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MHz, MeOD) δ 168.05, 142.95, 135.22, 133.81, 132.06, 129.35, 110.01. HRMS 
C9H7O3Cl [M-H]- Expected: 197.0011, Found: 197.0016. 
 
 
3-(2-chlorophenyl)-2-oxopropanoic acid (3-13c): Procedure 1 was followed using 2-
chlorobenzaldehyde. Yield 56% (0.3 g, 1.51 mmol). 1H NMR (400 MHz, MeOD) δ 8.32-
8.35 (d, J = 7.9 Hz, 1H), 7.38-7.40 (d, J = 8.1 Hz, 1H), 7.26-7.30 (t, J = 7.6 Hz, 1H), 
7.19-7.21 (t, J = 7.8 Hz, 1H), 6.89 (s, 1H); 13C NMR (125 MHz, MeOD) δ 167.97, 
143.77, 134.42, 134.04, 132.20, 130.31, 129.41, 127.73, 105.93. HRMS C9H7O3Cl [M-
H]- Expected: 197.0011, Found: 197.0010. 
 
3-(4-hydroxyphenyl)-2-oxopropanoic acid (3-14c): Procedure 1 was followed using 4-
hydroxybenzaldehyde. Yield 74% (1.3 g, 7.22 mmol). 1H NMR (400 MHz, MeOD) δ 
7.62-7.64 (d, J = 8.6 Hz, 2H), 6.75-6.77 (d, J = 8.8 Hz, 2H), 6.45 (s, 1H); 13C NMR 
(125 MHz, MeOD) δ 168.74, 158.19, 139.97, 132.41, 127.94, 116.15, 112.35. HRMS 
C9H8O4 [M-H]- Expected: 179.0350, Found: 179.0354. 
  
3-(3-hydroxyphenyl)-2-oxopropanoic acid (3-15c): Procedure 1 was followed using 3-
hydroxybenzaldehyde. Yield 88% (0.7 g, 3.89 mmol). 1H NMR (400 MHz, (CD3)2SO) 
δ 7.29 (s, 1H), 7.07-7.14 (m, 2H), 6.63-6.66 (m, 1H), 6.29 (s, 1H); 13C NMR (125 MHz, 
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(CD3)2SO) δ 166.28, 157.11, 141.56, 135.96, 129.02, 120.48, 115.78, 114.47, 109.76. 
HRMS C9H8O4 [M-H]- Expected: 179.0350, Found: 179.0348.  
 
3-(4-fluorophenyl)-2-oxopropanoic acid (3-16c): Procedure 1 was followed using 4-
fluorobenzaldehyde. Yield 71% (0.5 g, 2.74 mmol). 1H NMR (400 MHz, MeOD) δ 7.78-
7.81 (m, 2H), 7.02-7.07 (t, J = 8.9 Hz, 2H), 6.47 (s, 1H); 13C NMR (125 MHz, MeOD) 
δ 168.26, 164.52, 162.07, 142.02, 132.57, 132.65, 115.88, 116.10, 110.42. HRMS 
C9H7O3F [M-H]- Expected: 181.0306, Found: 181.0306. 
 
3-(4-cyanophenyl)-2-oxopropanoic acid (3-17c): Procedure 1 was followed using 4-
cyanobenzaldehyde. Yield 70% (0.05 g, 0.26 mmol). 1H NMR (400 MHz, (CD3)2CO) δ 
8.62 (d, J = 1.7 Hz, 1H), 8.01 (d, J = 8.6 Hz, 2H), 7.76 (d, J = 8.6 Hz, 2H), 6.60 (s, 1H); 
13C NMR (125 MHz, (CD3)2CO) δ 167.49, 145.32, 141.54, 133.02, 132.69, 132.65, 
131.03, 120.00, 110.87, 108.92. HRMS C10H7NO3 [M-H]- Expected: 188.0353, Found: 
188.0346.  
General Procedure 2: 1,4-diacetylpiperazine-2,5-dione119 (0.5 mmol) was dissolved 
in DMF (1 mL). Triethylamine (0.5 mmol) was added followed by corresponding 
aldehyde (0.5 mmol). The reaction mixture was stirred for 12 h at room temperature. 
It was extracted with DCM, washed with NH4Cl solution. The organic layer was dried 
over Na2SO4 and evaporated. Purification of the residue on silica gel afforded the 
product (benzylidene)-piperazine-2,5-dione intermediate. This intermediate (0.1 
mmol) was refluxed in 6 N HCl (4.0 ml) for 4 h. The reaction was cooled to room 
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temperature, extracted with ether, dried over Na2SO4 and evaporated to give the crude 
keto acid. It was recrystallized in water to give pure product.  
 
3-(3-methoxyphenyl)-2-oxopropanoic acid (3-18c): Procedure 2 was followed using 3-
methoxylbenzaldehyde. Yield 56% (0.5 g, 2.57 mmol). 1H NMR (400 MHz, MeOD) δ 
7.44 (t, J = 2 Hz, 1H), 7.20-7.29 (m, 2H), 6.79-6.82 (m, 1H), 6.46 (s, 1H), 3.79 (s, 3H); 
13C NMR (125 MHz, MeOD) δ 168.32, 161.04, 142.44, 137.66, 130.11, 123.52, 
115.80, 114.39, 111.51, 55.62. HRMS C10H10O4 [M-H]- Expected: 193.0506, Found: 
193.0495. 
 
3-(3-chlorophenyl)-2-oxopropanoic acid (3-19c): Procedure 2 was followed using 3-
chlorobenzaldehyde. Yield 56% (0.12 g, 0.60 mmol). 1H NMR (400 MHz, (CD3)2CO) δ 
7.96 (t, J = 1.96 Hz, 1H), 7.76 (dt, J = 7.8 Hz, 1H), 7.25-7.41 (m, 3H), 6.54 (s, 1H), 
4.28 (s, 0.6H), 4.05 (d, J = 6.2 Hz, 0.5H); 13C NMR (125 MHz, (CD3)2CO)) δ 166.54, 
137.85, 134.59, 130.74, 130.67, 129.80, 128.83, 127.99, 109.31. HRMS C9H7O3Cl [M-
H]- Expected: 197.0011, Found: 197.0005. 
General Procedure 3120: Substituted benzaldehyde (2 mmol) was dissolved in acetic-
anhydride (0.25 M). N-acetyl glycine (2.4 mmol) was added followed by sodium 
acetate (10 mmol). The reaction mixture was refluxed for 4 h at 140 oC. It was poured 
into crushed ice, stirred for 30 min. Precipitate was separated, washed with cold water, 
and dried under vacuum to afford the oxazolyl intermediate. This intermediate (0.4 
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mmol) was refluxed in 3 N HCl (4.0 ml) for 24 hours at 100 oC. The reaction was cooled 
to room temperature, extracted with ether, washed with 6 N HCl, dried over Na2SO4 
and evaporated to give the crude keto acid. It was recrystallized in water to give pure 
product. 
 
3-(3,4-dichlorophenyl)-2-oxopropanoic acid (3-20c): Procedure 3 was followed using 
3,4-dichlorobenzaldehyde. Yield 71% (0.06 g, 0.28 mmol). 1H NMR (400 MHz, 
(CD3)2CO) δ 8.1 (d, J = 1.89 Hz, 1H), 7.76 (dd, J = 8.49 Hz, 1H), 7.56 (d, J = 8.44 Hz, 
1H), 6.53 (s, 1H); 13C NMR (125 MHz, (CD3)2CO)) δ 166.39, 143.09, 136.55, 132.63, 
131.78, 131.29, 131.11, 130.27, 108.38. HRMS C9H6O3Cl2 [M-H]- Expected: 
230.9627.  
 
3-(2,4-dichlorophenyl)-2-oxopropanoic acid (3-20c): Procedure 3 was followed using 
2,4-dichlorobenzaldehyde. Yield 77% (0.35 g, 1.5 mmol). 1H NMR (400 MHz, MeOD) 
δ 8.34 (d, J = 8.79 Hz, 1H), 7.29-7.53 (m, 3H), 6.82 (s, 1H); 13C NMR (125 MHz, 
MeOD) δ 167.62, 144.44, 134.76, 133.96, 132.96, 131.83, 130.41, 129.95, 129.78, 
128.75, 128.35, 128.04, 127.61, 104.58. HRMS C9H6O3Cl2 [M-H]- Expected: 
230.9627.  
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2-oxo-3-(4-(trifluoromethyl)phenyl)propanoic acid (3-20c): Procedure 3 was followed 
using 3-trifluoromethylbenzaldehyde. Yield 90% (0.09 g, 0.41 mmol). 1H NMR (400 
MHz, (MeOD) δ 7.93 (td J = 8.15 Hz, 2H), 7.59 (d, J = 8.15 Hz, 2H), 6.51 (s, 1H); 13C 
NMR (125 MHz, MeOD) δ 167.71, 144.46, 140.44, 132.22, 130.82, 126.01, 125.97, 
125.94, 125.64, 125.61, 109.28. HRMS C10H7O3F3 [M-H]- Expected: 231.0227. 
2.7.3.2. Synthesis of Hydroxyimino (Oxime) Analogues 
General Procedure 4: The corresponding keto-acid (0.50 mmol) is dissolved in a 
solution of NaOH (1.51 mmol) in water (1 mL).  Hydroxylamine hydrochloride (0.76 
mmol) is added to the reaction and stirred overnight at room temperature. 1 N HCl is 
added to the reaction, the precipitated product is filtered and dried. The crude product 
is purified using flash chromatography (silica gel, 5% MeOH/DCM) as necessary. 
 
 
2-(hydroxyimino)-3-p-tolylpropanoic acid (2-15): Title compound was prepared 
following general procedure 4. Yield 55% (0.03 g, 0.16 mmol). 1H NMR (400 MHz, 
MeOD) δ 7.05-7.14 (m, 4H), 3.86 (s, 2H), 2.27 (s, 3H); 13C NMR (125 MHz, MeOD) δ 
166.90, 152.35, 136.96, 134.84, 129.96, 129.89, 30.51, 21.03. HRMS C10H11NO3 [M-
H]- Expected: 192.0666, Found:192.0673. 
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2-(hydroxyimino)-3-m-tolylpropanoic acid (2-16): Title compound was prepared 
following general procedure 4. Yield 74% (0.04 g, 0.21 mmol). 1H NMR (400 MHz, 
MeOD) δ 7.03-7.13 (m, 3H), 6.98 (d, J = 7.31 Hz, 1H), 3.87 (s, 2H), 2.28 (s, 3H); 13C 
NMR (125 MHz, MeOD) δ 166.88, 152.22, 139.03, 137.84, 130.61, 129.26, 128.02, 
127.02, 30.85, 21.42. HRMS C10H11NO3 [M-H]- Expected: 192.0666, Found:192.0656. 
 
 
2-(hydroxyimino)-3-o-tolylpropanoic acid (2-17): Title compound was prepared 
following general procedure 4. Yield 92% (0.12 g, 0.62 mmol). 1H NMR (400 MHz, 
(CD3)2CO) δ 7.01-7.10 (m, 4H), 3.88 (s, 2H), 2.35 (s, 3H); 13C NMR (125 MHz, 
(CD3)2CO) δ 167.77, 153.63, 137.10, 136.37, 130.67, 129.10, 126.82, 126.60, 28.37, 
19.93. HRMS C10H11NO3 [M-H]- Expected: 192.0666, Found:192.0652. 
 
 
2-(hydroxyimino)-3-(4-methoxyphenyl)propanoic acid (2-18): Title compound was 
prepared following general procedure 4. Yield 71% (0.08 g, 0.36 mmol). 1H NMR (400 
MHz, MeOD) δ 7.18 (d, J = 8.6 Hz, 2H), 6.79 (d, J = 8.8 Hz, 2H), 3.86 (s, 2H), 3.74 (s, 
3H); 13C NMR (125 MHz, MeOD) δ 167.48, 159.71, 153.20, 131.07, 130.09, 114.79, 
55.67, 30.16. HRMS C10H11NO4 [M-H]- Expected: 208.0615, Found:208.0601. 
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2-(hydroxyimino)-3-(3-methoxyphenyl)propanoic acid (2-19): Title compound was 
prepared following general procedure 4. Yield 72% (0.08 g, 0.37 mmol). 1H NMR (400 
MHz, MeOD) δ 7.13-7.17 (t, J = 8.1 Hz, 1H), 6.83 (m, 2H), 6.74 (dd, J = 8.3 Hz, 1H), 
3.89 (s, 2H), 3.75 (s, 3H); 13C NMR (125 MHz, MeOD) δ 166.87, 161.21, 152.07, 
139.41, 130.29, 122.35, 115.73, 112.86, 55.56, 30.95. HRMS C10H11NO4 [M-H]- 
Expected: 208.0615, Found:208.0612. 
 
 
2-(hydroxyimino)-3-(2-methoxyphenyl)propanoic acid (2-20): Title compound was 
prepared following general procedure 4. Yield 56% (0.07 g, 0.33 mmol). 1H NMR (400 
MHz, (CD3)2CO) δ 7.17 (t, J = 7.8 Hz, 1H), 7.00 (d, J = 7.6 Hz, 1H), 6.93 (d, J = 8.5 
Hz, 1H), 6.83 (t, J = 7.6 Hz, 1H), 3.90 (s, 2H), 3.82 (s, 3H); 13C NMR (125 MHz, 
(CD3)2CO) δ 165.17, 158.28, 151.76, 129.60, 28.34, 125.57, 121.06, 111.32, 55.72, 
25.53. HRMS C10H11NO4 [M-H]- Expected: 208.0615, Found:208.0607. 
 
 
3-(4-chlorophenyl)-2-(hydroxyimino)propanoic acid (2-21): Title compound was 
prepared following general procedure 4. Yield 56% (0.06 g, 0.28 mmol). 1H NMR (400 
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MHz, DMSO) δ 12.34 (br s, 1H), 7.33 (d, J = 8.5 Hz, 2H), 7.20 (d, J = 8.5 Hz, 2H), 3.79 
(s, 2 H); 13C NMR (125 MHz, MeOD) δ 166.71, 151.68, 136.88, 133.20, 131.63, 
129.40, 30. 39. HRMS C9H8NO3Cl [M-H]- Expected: 212.0120, Found: 212.0102. 
 
 
3-(3-chlorophenyl)-2-(hydroxyimino)propanoic acid (2-22): Title compound was 
prepared following general procedure 4. Yield 66% (0.15 g, 0.70 mmol). 1H NMR (400 
MHz, DMSO) δ 7.24-7.34 (m, J = 8.8 Hz, 3H), 7.17 (d, J = 7.3 Hz, 1H), 3.82 (s, 2H); 
13C NMR (125 MHz, DMSO) δ 165.16, 139.26, 132.81, 130.14, 128.32, 127.32, 
126.14, 29.64. HRMS C9H8O3NCl [M-H]- Expected: 212.0120, Found:212.0108. 
 
 
3-(2-chlorophenyl)-2-(hydroxyimino)propanoic acid (2-23): Title compound was 
prepared following general procedure 4. Yield 54% (0.02 g, 0.07 mmol). 1H NMR (400 
MHz, DMSO) δ 7.41-7.44 (m, 1H), 7.21-7.28 (m, 2H), 7.03 (m, 1H), 3.88 (s, 2H); 13C 
NMR (125 MHz, DMSO) δ 164.97, 149.01, 134.08, 132.83, 129.22, 129.11, 127.96, 
127.11, 27.93. HRMS C9H8O3NCl [M-H]- Expected: 212.0120, Found: 212.0134. 
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2-(hydroxyimino)-3-(4-hydroxyphenyl)propanoic acid (2-24): Title compound was 
prepared following general procedure 4. Yield 91% (0.10 g, 0.51 mmol). 1H NMR (400 
MHz, MeOD) δ 7.08 (d, J = 8.5 Hz, 2H), 6.66 (d, J = 8.5 Hz, 2H), 3.80 (s, 2H); 13C 
NMR (125 MHz, MeOD) δ 166.93, 156.93, 152.63, 131.06, 128.70, 116.13, 30.03. 
HRMS C9H9NO4 [M-H]- Expected: 194.0459, Found:194.0459. 
 
 
2-(hydroxyimino)-3-(3-hydroxyphenyl)propanoic acid (2-25): Title compound was 
prepared following general procedure 4. Yield 65% (0.07 g, 0.36 mmol). 1H NMR (400 
MHz, DMSO) δ 7.04 (t, J = 8.0 Hz, 1H), 6.55-6.62 (m, 3H), 3.72 (s, 2H); 13C NMR (125 
MHz, DMSO) δ 165.18, 157.22, 137.89, 129.09, 119.24, 115.44, 113.07, 48.52, 29.74. 
HRMS C9H9NO4 [M-H]- Expected: 194.0459, Found:194.0442. 
 
 
3-(4-fluorophenyl)-2-(hydroxyimino)propanoic acid (2-26): Title compound was 
prepared following general procedure 4. Yield 74% (0.08 g, 0.41 mmol). 1H NMR (400 
MHz, DMSO) δ 7.20-7.24 (m, 2H), 7.10 (t, J = 8.8 Hz, 2H), 3.79 (s, 2H); 13C NMR (125 
MHz, MeOD) δ 165.06, 161.94, 159.54, 150.03, 132.82, 132.79, 130.38, 130.30, 
115.12, 114.91, 29.06. HRMS C9H8NO3F [M-H]- Expected: 196.0415, Found: 
196.0398. 
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3-(4-cyanophenyl)-2-(hydroxyimino)propanoic acid (2-27): Title compound was 
prepared following general procedure 4. Yield 64% (0.09 g, 0.44 mmol). 1H NMR (400 
MHz, DMSO) δ 7.74 (d, J = 7.6 Hz, 2H), 7.37 (d, J = 8.1 Hz, 2H), 3.89 (s, 2H); 13C 
NMR (125 MHz, DMSO) δ 164.93, 149.11, 142.74, 132.26, 129.52, 118.77, 109.06, 
30.20. HRMS C10H8N2O3 [M-H]- Expected: 203.0462, Found: 203.0452. 
 
3-(3,4-dichlorophenyl)-2-(hydroxyimino)propanoic acid (2-28): Title compound was 
prepared following general procedure 4. Yield 66% (0.01 g, 0.04 mmol). 1H NMR (400 
MHz, MeOD) δ 7.38-7.43 (m, 2H), 7.20 (dd, J = 8.34 Hz, 1H), 3.89 (s, 2H); 13C NMR 
(125 MHz, MeOD) δ 166.80, 151.37, 138.94, 132.96, 132.01, 131.31, 131.14, 129.98, 
30.22. HRMS C9H7Cl2NO3 [M-H]- Expected: 245. 
 
 
3-(2,4-dichlorophenyl)-2-(hydroxyimino)propanoic acid (2-29): Title compound was 
prepared following general procedure 4. Yield 66% (0.02 g, 0.08 mmol). 1H NMR (400 
MHz, MeOD) δ 7.42 (d, J = 2.04 Hz, 1H), 7.21 (dd, J = 8.25 Hz, 1H), 7.09 (d, J = 8.34 
Hz, 1H), 3.98 (s, 2H); 13C NMR (125 MHz, MeOD) δ 166.88, 150.90, 135.71, 134.68, 
133.73, 131.82, 129.90, 128.07, 28.72. HRMS C9H7Cl2NO3 [M-H]- Expected: 245.97. 
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2-(hydroxyimino)-3-(4-(trifluoromethyl)phenyl)propanoic acid (2-30): Title compound 
was prepared following general procedure 4. Yield 48% (0.01 g, 0.03 mmol). 1H NMR 
(400 MHz, (CD3)2CO) δ 7.63 (d, J = 8.32 Hz, 2H), 7.52 (d, J = 8.32 Hz, 2H), 4.04 (s, 
2H); 13C NMR (125 MHz, (CD3)2CO) δ 166.89, 151.58, 142.85, 130.62, 129.84, 
129.52, 127.16, 126.20, 126.16, 124.46, 31.01. HRMS C10H8F3NO3 [M-H]- Expected: 
246.04.  
2.7.4. Protein Production and Purification of CtBP2 
Truncated CtBP2 (amino acids 31-384), which lacks both the N- and C-terminal 
domains, was expressed as a His6-tagged protein in BL21-CodonPlus®(DE3)-RIL 
competent cells (Stratagene).  Protein expression was induced in cultures with 200 
μM IPTG for 4 hours and cells were homogenized and incubated in the presence of 
NiNTA beads (Thermo Scientific).  CtBP2(31-384) was eluted with 300 mM imidazole 
after several washes and further purified by overnight dialysis and passage through a 
6-8,000 kDa MWCO filter (Fisher Scientific). Purity was assessed by Coomassie stain 
(Invitrogen).  
  
2.7.5. Inhibition of Dehydrogenase Activity of Recombinant CtBP (NADH 
inhibition assay) 
Purified CtBP2 in 50% glycerol was added to 150 μM NADH, 48 μM MTOB and various 
concentrations of inhibitor in buffer containing 25 mM HEPES, pH 7.1, 25 mM 
potassium chloride, and 1 mM DTT.  The final concentration of CtBP2 was 40 μg/mL 
(986 nM) per reaction.  Inhibitors dissolved in DMSO constituted 1% of the total 
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volume.  For compounds 4-13, inhibitor concentrations ranging from 300 μM to 10 μM 
and a no-drug (DMSO) control were tested.  For 9 and analogues 14a-m, inhibitor 
concentrations of 5 μM, 2.5 μM, 1 μM, 500 nM, 100 nM, 50 nM, 10 nM, and 0 nM 
(DMSO control) were used.  Three triplicate runs were performed for each inhibitor. 
Reaction components were added to 96-well UV-Star Microplates (Greiner Bio-One) 
and upon addition of CtBP, reactions were mixed vigorously and immediately read by 
a Synergy H1 microplate reader (BioTek).  Absorbance was recorded at A=340nm 
every 30 sec for 15 min at 25 °C to measure CtBP2 dehydrogenase function (NADH, 
but not NAD+ absorbs light at 340 nm).  Change in absorbance was plotted after 15 
minutes and IC50 concentrations were determined using Prism (Graphpad,Version 
5.04).  Representative IC50 curves for 2-14 (HIPP), 2-21 (4-Cl HIPP), and 2-22 (3-Cl 
HIPP) are shown below. 
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2.7.6 Inhibition of Cell Growth (MTT Assay) 
HCT-116 p53-/- colorectal cancer cell (~1,000 cells) in 100 μL media were plated in a 
96 well plate.  After a 24 hour incubation, inhibitors in DMSO were further diluted in 
NaHCO3 (0.8% diluted DMSO final volume/well) and added to plates at 4, 2, 1, and 
0.5 mM concentrations.  72 h after addition of inhibitor, 20 μL of MTT solution (Alfa 
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Aesar) was added to each well and cells were incubated a further 4 h.  Media was 
then aspirated and the MTT metabolic product formazan was resuspended in 200 μL 
DMSO.  Optical density was measured at 560 nm (subtracting background at 670 nm) 
using a microplate reader and IC50 concentrations were determined using Prism 
(Graphpad,Version 5.04). 
2.7.7. LDH Assay 
Three compounds – HIPP, 3-Cl HIPP and 4-Cl HIPP were tested for their ability to 
inhibit LDH (which is closely related to CtBP in function). Sodium oxamate (a known 
inhibitor of LDH) was used as the standard. Commercially available L-Lactic 
Dehydrogenase (from rabbit muscle) was purchased from Sigma-Aldrich (USA). Stock 
solutions of the compounds (15.36 mM in DMSO) were prepared. They were added 
(in amounts of 0, 3, 6, 12, 24, 96 and 192 μM final concentrations) to a reaction mixture 
containing 100 mM phosphate buffer (pH 7.2), LDH (0.5 U/mL – solution in 50% 
glycerol), 200 μM pyruvate and 300 μM NADH at 0 oC. The final DMSO concentration 
in all the wells was kept constant at 6.25%, and the final volume was 80 μL in each 
well. The enzyme inhibition was measured by monitoring change in levels of NADH 
over a period of 30 min. Absorbance was measured at 340 nm every 10 sec. The 
assay was performed three times in 96-well-clear bottom plates (in triplicate each time) 
using FlexStation plate reader (Molecular Devices) at 28 oC. The minimal 
concentration of compounds leading to 50% inhibition of LDH activity (IC50) was 
calculated using non-linear regression of the experimental data, using Prism software 
(GraphPad). 
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2.7.8. Oxime Stability Studies 
To study the stability of oximes under assay conditions, we ran HPLC samples (HIPP, 
3-Cl HIPP and 4-Cl HIPP) to check if the compounds hydrolyze during assay runs. In 
order to see if the compounds hydrolyze to parent phenylpyruvic acids, we ran controls 
of PPA, 3-Cl PPA and 4-Cl PPA. All the samples were dissolved in DMSO. Final 
concentration was 4 mM (15.36 mM DMSO stock was diluted in 25 mM phosphate 
buffer pH 7.2 to give final conc. of 4 mM). The samples were incubated at room 
temperature without shaking for 72 h. 20 μL aliquots were run on the HPLC at time 
points 0 min, 24 h, 48 h and 72 h. The graphs of the runs are shown below. 
Solvents used – Water (with 0.1% formic acid), ACN (with 0.1% formic acid) 
Conditions: Initial 0 min 5% ACN/95% water,  
0-10 min 5% → 95% ACN/5% water,  
10-12 min 95% → 5% ACN/95% water 
Column Flow: 1.000 mL/min  
Stoptime: 12.00 min 
Injection Volume: 20.0 µL  
Wavelengths observed: 254 nm and 280 nm. 
 
HIPP 0 min 
 
 72 
 
 
HIPP 24 h 
 
HIPP 48 h 
 
HIPP 72 h 
 
Phenylpyruvic acid 
As seen in the graphs above, there is no significant change in the retention times 
between 0 min vs 24 h, 48 h and 72 h of HIPP, which shows that the oxime is stable 
up to at least 72 h. This retention time is different from that of phenylpyruvic acid, 
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which shows that the oxime is not getting hydrolysed to the parent keto acid. Similar 
results were obtained with 3-Cl HIPP and 4-Cl HIPP (shown below). 
 
3-Cl-HIPP 45 min 
 
3-Cl-HIPP 24 h 
 
3-Cl-HIPP 48 h 
 
3-Cl-HIPP 72 h 
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4-Cl-HIPP 0 min 
 
4-Cl-HIPP 27 h 
 
4-Cl-HIPP 48 h 
 
4-Cl-HIPP 72 h 
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4-Cl-phenylpyruvic acid 
 
2.7.9. HINT Scoring  
Analogues of hydroxyimine 2-14 were modeled with SYBYL-X 2.1 (Tripos Inc.); 
Gasteiger–Hückel charges were assigned and models were energy minimized with 
the Tripos forcefield (10,000 iterations, termination gradient of 0.01 kcal/mol-Å).  The 
crystal structure of CtBP1/HIPP/NAD+ was used as the target for docking studies using 
GOLD v5.2, with the binding defined as all the residues within 10 Å of the bound ligand 
2-14.  Since the ligands are analogues of 2-14, it is reasonable to expect that they will 
adopt binding modes very similar to that of the parent compound. Thus, the binding 
pose of 2-14 defined a scaffold match constraint, i.e., the common substructure forced 
the corresponding atoms of ligands to lie in the exact, or very close, position within the 
binding site.  Default GOLD genetic algorithm parameters were used and a total of 50 
solutions per compound were generated. The generated conformations were re-
ranked using the free-energy based HINT force-field, that quantifies all non-bonded 
interactions in a biological environment, including hydrogen-bonding, electrostatic 
interactions, hydrophobic interactions as well as desolvation energy. The ligand in its 
most energetically favorable binding conformation and the CtBP1/NAD+ complex were 
subjected to minimization (Powell, 2500 iterations, termination gradient 0.01 kcal/mol-
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Å), to remove steric clashes and optimize the protein-ligand interactions within the 
active site.  HINT scores for the thus optimized complex were then recalculated. 
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Investigation of the Scope of Palladium Multi-Walled Carbon Nanotubes (Pd-
MWCNT) Catalyst in C–H Activation Reactions 
 
3. C–H Activation 
 
3.1. Introduction 
 
Organic molecules comprise chains or rings of carbon atoms, capped with hydrogen 
atom(s), and with or without heteroatoms (mostly nitrogen, oxygen, halogens, sulfur, 
and phosphorous). These form simple hydrocarbons, natural products, proteins, 
pharmaceuticals, plastics and agrochemicals. Carbon–hydrogen bonds are present 
ubiquitously in nature (Figure 3-1).121 
 
                 Figure 3-1. Ubiquitous nature of C-H bonds 
Above figure from “C–H Bond Functionalization in Complex Organic Synthesis,” Kamil Godula and Dalibor Sames. Science 
2006, 312, 67-75. Reprinted with permission from AAAS. 
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          Scheme 3-1. Traditional organic synthesis (A) vs C–H functionalization (B) 
 
Organic chemistry involves transformation of functional groups or highly reactive 
structural features. C–H bonds are not considered as functional groups generally. In 
traditional approaches, the presence of a heteroatom (halogen, oxygen) or 
unsaturation is essential for the installation of a new bond, i.e. functional groups are 
installed only on pre-functionalized substrates for the purpose of reactivity and to 
achieve selectivity (Scheme 3-1).121 This forms the basis of all syntheses. Synthesis 
of pre-functionalized substrates itself adds additional steps to the synthetic scheme of 
the final product (Scheme 3-2).121 This is inefficient as it adds many steps to the overall 
synthetic route.  
 
 
                          Scheme 3-2. Comparison of traditional and C-H activation approaches 
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Although this is not an expensive approach on small scale reactions, it is very cost-
ineffective in the case of large scale reactions, especially in industries. Thus, solving 
this issue will be very atom-economical and time-efficient. 
 
 
One of the major challenges in organic chemistry has been the direct conversion of 
carbon–hydrogen bonds into carbon–halogen, carbon–sulfur, carbon–nitrogen, and 
carbon–carbon bonds using mild and selective methods. These transformations are 
very useful as C–H bonds are ubiquitous in nature. Overcoming this challenge would 
be of great use in the field of organic chemistry with wide applications in synthesis of 
pharmaceutical products, natural products, polymers, and agrochemicals.  
Direct transformation of a C–H bond to introduce a new functional group is the key to 
overcome the above challenges. For example, the final product in scheme 3-2 can be 
obtained by displacing just one hydrogen atom. This direct and selective 
functionalization of a C–H bond by an organometallic catalyst is termed “C–H 
Activation” (Scheme 3-3).122 This approach is atom- and step-economical, and can be 
used to make synthetic connections that are not possible by traditional methods.  
 
The four main challenges in direct C–H functionalization reactions are: reactivity, 
chemoselectivity, regioselectivity and stereoselectivity.123 
Scheme 3-3. C-H activation 
 80 
 
Reactivity challenges arises because of the inert nature of most of the carbon-
hydrogen bonds (pKa >30-35, BDE 85-105 kcal/mol). Though many oxidation 
reactions are thermodynamically favorable, the cleavage a of C–H bond has a high 
kinetic barrier. This challenge has been overcome by many groups of researchers by 
the use of transition metals. Transition metals (M) react with C–H bond to give C–M 
bonds, which are much more reactive than the corresponding C–H bonds. These C–
M bonds can then be functionalized into various functional groups in a single step.124  
Chemoselectivity challenges arises because of the difficulty in stopping reactions at 
the required oxidation state, over-oxidized products are generally thermodynamically 
favored. This challenge has been overcome by using excess substrate relative to 
oxidant, low conversion of reactions.  
Regioselectivity challenges arises because organic compounds invariably contain 
several C–H bonds in different environments. This challenge has been overcome 
through different approaches. The most common approach has been the use of 
“directing groups” or “coordinating ligands” that are basic and coordinate to the metal 
center, and deliver the catalyst to a proximal C–H bond. The intramolecular directing 
groups are basic groups containing nitrogen such as pyridine or oxazole. This “ligand-
directed C–H activation” has been reported at several transition metal centers such as 
Pd, Pt, Ru and Rh. Other approaches such as using substrates containing weaker C–
H bonds, having five- or six-membered cyclometalated species, and variation of 
ligand-catalyst systems have been employed to achieve selectivity.  
Stereoselectivity challenges are involved in the difficult process of generating new 
stereocenters in a dia- or enantio- selective manner. This has not been explored as 
much as other challenges. Approaches such as use of stereo center containing 
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substrates, or chiral catalyst-ligand systems have been used to overcome this 
challenge.  
 
3.1.1. Brief Examples of Use of C-H Activation in Synthesis 
3.1.1.1. C–H activation in natural product synthesis 
 
                    Figure 3-2. C-H activation steps in Teleocidin B-4 core synthesis 
Above figure reprinted with permission from “C-C Bond Formation via C-H Bond Activation: Synthesis of the Core of Teleocidin 
B4.” Brian D. Dangel, Kamil Godula, So Won Youn, Bengü Sezen, and Dalibor Sames. JACS 2002, 124, 11856-11857. 
Copyright 2002, American Chemical Society. 
 
C–H activation has been used in natural product synthesis. Dangel et al reported the 
synthesis of a complex natural product fragment Teleocidin B-4 core by employing 
four C–C bond forming steps (alkenylation of alkyl group, Friedel-Crafts reaction, 
carbonylation and alkenylation of phenol, Figure 3-2).125  
 
Starting from Schiff base 1, cyclometallation with PdCl2 gives the palladacycle 2, which 
undergoes reaction with boronic acid to afford 4. Treatment with MeSO3H catalyzes a 
Friedel-Crafts reaction to afford intermediate 5, which undergoes cyclopalladation to 
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afford 7 and 8 by carbonylation and hydrolysis of the Schiff base (Scheme 3-4). 
Intermediate 7 is then alkylated to afford intermediate 10, which undergoes Pd-
catalyzed alkenylation to afford the final product Teleocidin B-4 core (Scheme 3-5).125 
 
Scheme 3-4. Synthesis of intermediate 7 
Above figure reprinted with permission from “C-C Bond Formation via C-H Bond Activation: Synthesis of the Core of Teleocidin 
B4.” Brian D. Dangel, Kamil Godula, So Won Youn, Bengü Sezen, and Dalibor Sames. JACS 2002, 124, 11856-11857. 
Copyright 2002, American Chemical Society. 
 
 
                                  Scheme 3-5. Synthesis of Teleocidin B-4 core 
                   Conditions: a). t-BuOK, THF; b). BBr3, DCM; c). Pd(OAc)2, P(t-Bu)3, Cs2CO3, DMA. 
Above figure reprinted with permission from “C-C Bond Formation via C-H Bond Activation: Synthesis of the Core of Teleocidin 
B4.” Brian D. Dangel, Kamil Godula, So Won Youn, Bengü Sezen, and Dalibor Sames. JACS 2002, 124, 11856-11857. 
Copyright 2002, American Chemical Society. 
 
 83 
 
3.1.1.2. C–H activation in late-stage diversification  
Development of new drugs requires the identification of lead compounds, and design 
of analogs with improved activities. Thus, methods to quickly form analogs from a core 
structure is highly desirable. In efforts towards this, C–H activation has also been 
applied in “structural core diversification” in which various C–H bonds in a complex 
molecule are selectively transformed to produce series of analogues from a common 
substrate (Scheme 3-6).121 This is highly advantageous over traditional approaches 
where multi-step and usually different synthetic routes are needed to arrive at series 
of analogs.  
 
 
Scheme 3-6. Structural core diversification 
 
Late-stage diversification has been used in the synthesis of drug candidates, organic 
light-emitting diodes (OLEDs), perylene tetracarboxylic acid bisimide (PBI), metal 
organic frameworks (MOFs) and polymers (Figure 3-3).126  
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     Figure 3-3. C-H activation in late-stage diversification applications 
Above figure reprinted by permission from Macmillan Publishers Ltd: Nature Chemistry, “C-H bond activation enables the rapid 
construction and late-stage diversification of functional molecules.” Joanna Wencel-Delord and Frank Glorius. 2013, 5, 369-
375. Copyright 2013. 
Yu et al reported the late-stage diversification of celecoxib, an anti-inflammatory drug 
(Scheme 3-7).127 Sulfonamide group is an essential part of the pharmacophore for 
these compounds, converting it to perfluoroaryl sulfonamide allowed for its use as a 
directing group. Using Pd catalysis, ortho-directed C–H activation led to the synthesis 
of various ortho-substituted analogues in acceptable yields by olefination, 
carboxylation, carbonylation, iodination, arylation and alkylation reactions. This is 
advantageous over traditional approaches as it is more time-saving, and can install 
groups that could be unfeasible by non C–H activation reactions. 
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     Scheme 3-7. Late-stage diversification of celecoxib by C-H activation 
Itami and Wunsch reported the late-stage diversification of σ1 receptor ligands 
containing a spirocycle (Scheme 3-8).128 Based on the hypothesis that the aryl residue 
on the α-position of thiophene would lead to better activity and selectivity, they carried 
out Pd-catalyzed C–H activation (arylation) reactions. Introduction of aryl groups on 
the thiophene ring at various positions afforded rapid synthesis of analogues which 
were used in receptor-binding studies.  
 
     Scheme 3-8. Late-stage diversification of σ1 receptor ligands by C-H activation 
Late-stage diversification has applications outside of medicinal chemistry as well. It 
can be used where ‘lead optimization’ is required. It has been used in synthesis of 
compounds for optical applications in electronic devices with digital displays. 
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Triscyclometalllated Ir (III) complexes are useful as they have high emission-quantum 
yields and longer lifetimes. Late-stage diversification has been used to synthesize 
several analogues of such complexes.  
3.2. C–H Activation by Palladium Catalysts 
 
Homogenous transition metal catalysts have been extensively studied in C–H 
activation reactions to produce aryl or alkyl halides, alcohols, amines and aryl 
compounds. These transformations can occur through two general mechanisms – 
“organometallic” and “coordination.”129 
In the “organometallic” mechanism, there are two steps (Scheme 3-9). The first step 
involves cleavage of a C–H bond to afford a C–M bond (M is a transition metal). The 
second step involves functionalization of a C–M bond by an external reagent to afford 
the product. The structural and electronic nature of the organometallic intermediate 
dictates the regio-selectivity of the functionalization, which usually occurs at the less 
hindered C–H bonds in the molecule.  
 
 
Scheme 3-9. Organometallic mechanism 
In the “coordination” mechanism, higher oxidation state metal complexes that contain 
activated ligand (X, metal -oxo/imido/carbene) are formed (Scheme 3-10). This is 
followed by reaction of X with the C–H bond, either through direct insertion or H-atom 
abstraction, to finally afford the product. In this mechanism, the substrate undergoing 
C–H activation does not interact directly with the transition metal, but only interacts 
with the ligand (X). 
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 Scheme 3-10. Coordination mechanism of C–H activation 
 
This dissertation focuses on Pd-catalyzed C–H activation reactions. Palladium has 
several advantages over other transition metal catalysts.124  
Palladium is much cheaper than Pt and Rh (Figure 3-4). Pd centers can be used to 
install a variety of bonds, such as C–O, C–halogen, C–N, C–S and C–C. Only few 
other catalysts can catalyse such bond formations. This is because Pd is compatible 
with a variety of oxidants. Pd can be utilized to achieve C–H activation not only at sp2 
centers, but also at sp3 centers. Pd catalysed C–H activation reactions are not 
sensitive to air and moisture; this makes it an attractive catalyst for industrial 
applications. 
 
 88 
 
 
         Figure 3-4. Cost comparison of transition metals 
 
3.3. Mechanism of C–H activation 
 
3.3.1. N-Chelation-Directed C–H activation 
 
Coordination-directed metalation is one of the approaches for C–H activation 
reactions. It can be applied to both sp2 and sp3 carbons. This approach utilizes 
heteroatoms such as oxygen or nitrogen (which are in proximity to the C–H to be 
activated) to coordinate with the transition metal. This gives rise to a five- or six-
membered metallocycle, which is very reactive and subsequently forms the products. 
In this dissertation, we will focus on N-chelation-directed C–H activation. Examples of 
selective C−H to C−O,130-136 C−Halogen,130, 137, 138  C−C,139, 140 C−N,141, 142 C−F,143, 144 
and C−CF145 transformations using N-chelation-directed palladium catalysis have 
been reported in the literature. 
                                Aug         Sep         Oct         Nov         Dec         Jan         Feb  
                               2015        2015       2015       2015       2015        2016      2016 
 
Price 
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The mechanism is explained in detail in the scheme below (Scheme 3-11): 
In the first step, Pd(II) catalyst undergoes insertion into the proximal C–H bond to give 
a five- or six-membered palladacycle. The selectivity in this “chelation-directed” step 
is driven by directing groups such as nitrogen or oxygen that are basic in nature and 
direct the catalyst to a specific C–H bond. In the second step, usually an oxidant 
containing a functional group oxidizes Pd(II) to Pd(IV).146, 147 This is in contrast to the 
traditional coupling reactions that undergo Pd(0)/Pd(II) cycle. In the last step, reductive 
elimination causes Pd(II) to be regenerated, and the functional group is transferred to 
the activated C–H bond. 
 
        Scheme 3-11. Pd(II)/Pd(IV) catalytic cycle for N-chelation-directed C-H activation reactions 
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3.4. Carbon–Oxygen, Carbon–Halogen, Carbon–Carbon Bond Forming 
Reactions 
  
In the past two decades, C–H activation has been reported by several groups to make 
C–O, C–halogen, C–N, C–S and C–C bonds. This chapter focuses on the 
oxygenation, halogenation and arylation reactions catalyzed by palladium catalysts. 
This section focuses on homogenous palladium catalysts. Solid-supported and 
heterogenous catalysts will be discussed in section 3.5. 
 
3.4.1. Carbon–Oxygen Bond Forming Reactions  
Pd-catalyzed ortho-oxygenation reactions use various oxidants. Reactions that utilize 
Pd(OAc)2 catalyst and PhI(OAc)2 have been reported. In these reactions, nitrogen 
containing groups such as pyridine,130, 148 pyrazole,130  isoxazoline,148 imine,130  oxime 
ether149 function as directing groups to direct the acetoxylation to the ortho- position 
(Scheme 3-12). Ketones and aldehydes are poor directing groups, and hence do not 
undergo acetoxylation under these conditions. 
 
Scheme 3-12. Palladium-catalyzed N-chelation-directed oxygenation reactions 
The acetoxylation reactions are carried out under ambient air and moisture conditions. 
Many functional groups in the molecules are well tolerated such as:  aryl halides, nitro 
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groups, ketones, oximes. These features make Pd-catalyzed oxygenation reactions 
very attractive.  
When a substituent is present at the meta- position, the less hindered ortho- position 
undergoes acetoxylation. 
 
                         Scheme 3-13. Effect of solvent on oxygeantion reactions 
Switching the solvent leads to the installation of various alkoxy groups in the 
substrates. For example, MeOH solvent installs -OMe and EtOH solvent installs -OEt 
(Scheme 3-13).130 PhI(OAc)2 might be forming PhI(OR)2 in situ.150 The following 
mechanism has been proposed for C-H acetoxylation (Scheme 3-14). 
 
                                Scheme 3-14. Mechanism of C-H acetoxylation 
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Other oxidants that have been used in these reactions are oxone, IOAc,151 and 
dioxygen (Scheme 3-15).132 
 
                                  Scheme 3-15. C-H acetoxylation by IOAc 
IOAc is generated in situ by reacting I2 with PhI(OAc)2 or AgOAc. The mechanism at 
work when IOAc is utilised is: chelation-directed C–H activation, oxidation of PdII to 
PdIV, reductive elimination forming C–I bond, displacement of I- by OAc-. 
 
3.4.2. Carbon–Halogen Bond Forming Reactions 
 
Pd catalyzed C–H activation is an efficient method to install halogens such as Cl, Br 
and I. This was first reported in 1970, using Pd for the chlorination of azobenzene 
(Scheme 3-16).152 Although this reaction used Cl2, and gave rise to a mixture of 
isomers, there have been a lot of improvements since then in the use of more practical 
oxidants and improvement of selectivity.   
 
 
                  Scheme 3-16. Pd-catalyzed chlorination of azobenzene 
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 Scheme 3-17. Halogenation of benzo[h]quinoline 
 
Halogenation reactions catalyzed by Pd(OAc)2 using chlorinating agent N-
chlorosuccinimide (which also acts as an oxidant) gives ortho- chlorinated 
benzo[h]quinoline product in excellent yields. In a similar reaction, using NBS gives 
the brominated product (Scheme 3-17).130, 138  
On the other hand, the more reactive PhICl2 gives the 5-chlorinated product. This 
reaction occurs without N-chelation in the presence or absence of Pd catalyst 
(Scheme 3-17). Thus, Pd catalysts can be used to afford products that are 
complementary to the products obtained by electrophilic substitution reactions. Below 
are some more examples. In the presence of Pd, N-chelation-directed ortho- 
halogenation occurs. In the absence of Pd, electrophilic aromatic substitution occurs 
(Scheme 3-18).138 
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Scheme 3-18. Pd-catalyzed N-chelation-directed and non-catalyzed halogenation reactions 
 
The halogenation reactions using N-halosuccinimides and Pd catalysts has been 
applied to a wide variety of substrates with basic directing groups such as pyridines, 
oxime ethers, isoxazolines, isoquinolines (Scheme 3-19).137, 138 Using 2.5 equivalents 
of N-halosuccinimide gives the di-ortho-halogenated product. In the presence of a 
meta- substituent, the less hindered ortho- position is halogenated.  
 
Scheme 3-19. Pd-catalyzed N-chelation-directed halogenation reactions 
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Mechanism of halogenation: There are two proposed models of halogenation. 
Pd(II)/Pd(IV) cycle (Scheme 3-20). NCS is a strong oxidant that oxidizes Pd(II) to 
Pd(IV).147 
 
Scheme 3-20. Mechanism of halogenation by Pd catalyst – Pd(II)/Pd(IV) cycle 
 
Or, Pd(III)-Pd(III) dimer cycle which occurs in the presence of PhICl2 (Scheme 3-21).153   
    
 
 
Scheme 3-21. Mechanism of halogenation by Pd catalyst – Pd(III)/Pd(III) cycle 
 
Other halogenating agents that have been used in C-H activation reactions are CuCl2, 
CuBr2 (Scheme 3-22).137 
                       
Scheme 3-22. Pd-catalyzed halogenation reaction by CuCl2 
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          Scheme 3-23. Pd-catalyzed halogenation by Suarez-type reagent 
 
Yu et al have reported the use of Suarez-type reagents (XOAc) for halogenation of sp2 
and sp3 C-H bonds (Scheme 3-23).154  
 
Carbon-fluorine bond formation reactions have been carried out using Pd catalysts 
and electrophilic fluorinating reagents (Scheme 3-24).143 This is a very important 
transformation as it can be applied to PET imaging using radioactive fluorine. Instead 
of re-developing synthetic routes to incorporate radioactive fluorine, it can be easily 
installed through C-H activation reactions such as below in the final stages of the 
synthetic routes. This would be a time- and cost-efficient process.  
 
 
         Scheme 3-24. Pd-catalyzed fluorination reactions 
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3.4.3. Carbon–Carbon Bond Forming Reactions 
 
C–C bond formation is one of the most important reactions in organic chemistry. 
Traditional carbon–carbon bond forming reactions include coupling reactions such as 
Heck, Suzuki and Stille coupling reactions that utilize the Pd(0)/Pd(II) cycle, which 
have led to an immense progress in the synthesis of organic molecules. But there is 
still a need for improvement in the atom-economy, and cost-efficient processes. One 
major disadvantage of these coupling reactions is that all of them require two pre-
functionalized substrates. This adds additional steps in the synthesis of the final 
product. In efforts to overcome these disadvantages, C–H activation chemistry has 
been developed as an alternative, in which carbon–carbon bond formation is achieved 
using one or zero pre-functionalized substrates.  
The general reaction conditions for coupling reactions include homogenous Pd 
catalyst, base, ligand, and a solvent. Because the C–H bonds are inert (high 
dissociation energy), usually high temperatures (>100 oC) and Pd catalyst loading (5-
20 mol%) are required for the reactions to take place. In heterocyclic structures where 
the C–H bond is activated due to the presence of a heteroatom, the coupling reactions 
can be run at lower temperatures155, 156 and catalyst loading.157, 158 Pd(OAc)2 has been 
shown to catalyze arylation of substrates using diphenyliodinium salts as the arylating 
agents. This reaction is driven by N-chelation of Pd. Aryl pyridines, quinolines, 
oxazolidinones can undergo arylation reactions as they possess basic nitrogen 
chelating group which directs arylation to the ortho- position (Scheme 3-25).139, 159-161 
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     Scheme 3-25. Pd-catalyzed C–H arylation reactions using [Ph2I]BF4 
 
To install substituted aryl groups, asymmetrical arylating agents [Mes-I-Ar]BF4 can be 
used. Due to sterics, the bulky mesityl group is not transferred, and only the Ar group 
gets transferred selectively (Scheme 3-26).  
 
        Scheme 3-26. Pd-catalyzed C–H arylation reactions using asymmetrical arylating reagents 
 
The proposed mechanism of these arylation reactions is slightly different from that of 
the oxygenation and halogenation reactions. The catalyst resting state is Pd(II) 
monomeric species. It forms the cyclometalated dimer, which is oxidized by the 
arylating agent to give Pd(IV)/Pd(II) adduct (in some cases it is called as Pd(III)-Pd(III) 
species). This undergoes reductive elimination to afford the arylated product (Scheme 
3-27).140 
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   Scheme 3-27. Mechanism of Pd-catalyzed C–H arylation 
 
Another example of sp2 C–H arylation that utilizes Pd(OAc)2 and AgOAc has been 
reported. Amide162 and oxime ether163 containing substrates undergo arylation with 
aryl iodides to afford the coupled product fluorenones (Scheme 3-28). These reactions 
are tolerant to various functional groups. 
 
           Scheme 3-28. Fluorenone synthesis by C–H arylation 
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              Scheme 3-29. Pd-catalyzed arylation reaction of aminoquinoline 
Arylation of unactivated sp3 C–H bonds has also been achieved under similar 
conditions. Pyridines,164 aminoquinolines165 function as the directing groups (Scheme 
3-29). 
The above reactions that utilize Ag have been proposed to go through Pd(II)/Pd(IV) 
cycle. Ag salt is necessary for regenerating the Pd catalyst. Mechanistic studies have 
been conducted on benzoic acids (Scheme 3-30).166 
 
 
Scheme 3-30. Mechanism of Pd-catalyzed arylation with AgOAc 
 
C–H Arylation without Prefunctionalized Arylating Reagents: 
Reactions involving Pd-catalyzed ligand-directed arylations have been reported which 
do not require the presence of prefunctionalized substrates. As an example, the 
dimerization of arylpyridine in the presence of Pd(OAc)2 using oxone as oxidant 
(Scheme 3-31).167 Meta substituents on the aryl ring resulted in low site selectivity of 
arylation, in contrast to C–H arylation at Pd(II) centers.   
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                            Scheme 3-31. Dimerization of arylpyridine 
So, the following pathway has been proposed for this type of arylation reactions.167 
Cyclometalation at Pd(II) followed by oxidation of Pd(II) to Pd(IV) by oxone, 
cyclometalation at Pd(IV), and reductive elimination to give the arylated product and 
release of Pd(II) (Scheme 3-32). 
 
                       Scheme 3-32. Pd-catalyzed C–H arylation mechanism with oxone 
More recently, a general N-chelation directed Pd(OAc)2 catalyzed oxidative cross 
coupling reaction on benzo[h]quinoline has been reported. This reaction uses Ag2CO3 
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as the oxidant, benzoquinone as the promoter, DMSO to protect the catalyst.168 This 
reaction was shown to have a wide scope (Scheme 3-33). 
 
Scheme 3-33. Oxidative cross coupling reaction on benzo[h]quinoline 
These reactions are proposed to occur through the following mechanism: 
cyclopalladation, Ar-H activation, reductive elimination to afford the arylated product, 
oxidation of Pd(0) to Pd(II). Benzoquinone helps in the reductive elimination step 
(Scheme 3-34).168-170 
 
Scheme 3-34. Mechanism of oxidative cross coupling reaction on benzo[h]quinoline 
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3.5. Pd-MWCNT Catalyst 
Homogenous catalysts such as palladium acetate show high conversion of substrates 
to products because of easy access to all catalytic sites, but it is very difficult to remove 
the catalyst from the reaction mixture due to its high solubility. Thus, commercialization 
of homogenous catalyzed reactions has been rare.171 This has led to the development 
of heterogeneous and solid-supported catalysts in which the catalyst is in a different 
physical state from the solvent, and hence can be easily removed from the reaction 
mixture.172 This makes the process of purification less tedious. Such catalysts can also 
be reused/recycled, which makes the process very economical.  
 
In heterogeneous catalysis, reactants are adsorbed on the solid-supported catalyst 
surface, undergo reaction catalyzed by transition metal catalyst such as palladium, 
products get desorbed from the catalyst surface, and are extracted from the reaction 
mixture. Another mechanism of solid-supported catalysis is the “leaching-
redeposition” mechanism in which solid-supported Pd(0) nanocatalyst is oxidized to 
Pd(II) and leaches from the support, catalyzes the conversion of substrate to product 
in the reaction mixture, undergoes reduction to Pd(0) and is redeposited on the 
support. This can be tested by two experiments – hot filtration and three-phase test.173 
In the hot filtration test, a portion of the reaction mixture is filtered midway through the 
reaction, and fresh reagents are introduced. Further conversion indicates presence of 
soluble Pd species. Absence of conversion indicates absence of soluble Pd species, 
but it could also mean that there is a fast leaching-redeposition of the Pd species, 
which cannot be measured. Three-phase test174 is more reliable as a test for 
heterogeneity – one substrate is immobilized on a solid-support, and the reaction is 
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carried out using a solid-supported catalyst and a soluble substrate. Product formation 
indicates soluble Pd species catalyzing the reaction.   
 
New supports and catalysts are being continuously developed. Several materials such 
as polymers,175 dendrimers,176 metal oxides177 and carbonaceous materials178 have 
been used as solid supports for Pd and other transition metal catalysts. Ideal 
properties for the solid supports are – high surface area, chemical inertness, thermal 
and mechanical stability. 
 
Palladium metal has been shown to have a good catalytic activity in the form of 
nanoparticles. Optimization of shape and size of these nanoparticles is essential for 
improving catalytic activity.179 Metal-decorated carbon nanotubes (CNTs) – single-
walled and multi-walled (Figure 3-5)180 – are increasingly being used for many 
applications such as optics, electronics and catalysis. They have high chemical 
stability and surface area which makes them very efficient as catalysts. Graphene is 
a 2D mono-layered structure of graphite packed into a honeycomb-like lattice. It has 
excellent properties of thermal and mechanical stability. Reduction of graphene oxide 
by hydrazine was an early method to synthesize graphene sheets.181 3D derivatives 
of graphene are single walled carbon nanotubes (SWCNT) and multi-walled carbon 
nanotubes (MWCNT). These have been shown to have excellent catalytic activity. 
SWCNT consists of a single layer of graphene wrapped into a cylindrical column. The 
synthesis of SWCNT is very difficult, and is achieved by chemical vapor deposition. 
MWCNT have multiple sheets of graphene wrapped up into cylinders of varying 
diameters. These can be prepared by chemical vapor deposition as well. MWCNT 
have better stability compared to SWCNT owing to their multiple layers.  
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                 Figure 3-5. Single-walled and multi-walled carbon nanotubes 
The above figure is from “Nanostructures: a platform for brain repair and augmentation,” Ruxandra Vidu, Masoud Rahman, 
Morteza Mahmoudi, Marius Enachescu, Teodor D. Poteca and Ioan Opris. Front. Syst. Neurosci. 2014, 8, 91, 1-24. 
 
Scheuermann et al have reported the synthesis of graphene supported palladium 
nanoparticles.182 The synthesis of carbon nanotubes is complex and expensive, is 
achieved through lasers, vapor deposition and other techniques.  
 
Palladium is deposited on the nanotubes by the solvent-free methods of mortar-pestle 
or ball-milling, or with a solvent-based method. A schematic representation of of Pd 
decorated on MWCNT is shown in Figure 3-6.183  
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                            Figure 3-6. Pd decorated on MWCNT 
The Gupton lab has provided us with Pd-MWCNT catalyst for carrying out C–H 
activation reactions. Multi-walled nanotubes have an outer diameter of 6-9 mm, length 
5 µm and 95% carbon. In the mortar-pestle method, the carbon nanotubes are mixed 
with palladium acetate and ground using mortar and pestle until homogenous mixture 
of Pd-MWCNT is obtained. In the ball-mill method, carbon nanotubes and palladium 
acetate along with zirconia balls are placed in a ball mill and shaken mechanically 
(back-and-forth 5.9 cm, side-to-side 2.5 cm, 115 volts, 1060 cycles/min) to afford Pd-
MWCNT.  
 
The major advantages of solid-supported catalysts over that of homogenous catalysts 
are: recyclability, less/no contamination of products by residual metal, and ease of 
filtration and removal of catalyst from the reaction mixture. 
 
The first arylation catalyzed by heterogenous Pd was reported in 1982 by Nakamura 
et al.184 Arylation on muscimol was achieved using Pd/C catalyst on substituted 
isoxazoles (Scheme 3-35). 
Reactant
Product
Outer wall of 
MWCNT
Pd
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                     Scheme 3-35. Arylation of isoxazole catalyzed by Pd on carbon 
Fagnou et al used Pd(OH)2 supported on activated charcoal (Pearlman’s catalyst) for 
the arylations (intra- and inter-molecular) of arenes (Scheme 3-36).185 
 
             Scheme 3-36. Arylation of arenes using Pearlman's catalyst 
There have been reports that have used Pd-CNT (carbon nanotubes) to achieve 
Suzuki-Miyaura cross-coupling reaction. Suzuki reaction is a very powerful method to 
synthesize biaryl compounds. Usually Suzuki reactions require the presence of a 
ligand or an additive to prevent the aggregation of Pd0 during the course of the 
reaction.  
 
Zhang et al reported a ligandless and additive-free Suzuki reaction using Pd-CNT as 
the catalyst (Scheme 3-37).186 Excellent yields were achieved with various aryl 
bromides (both electron withdrawing and electron donating).  
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                           Scheme 3-37. Arylation of aryl bromides catalyzed by Pd-CNT 
Siamaki et al reported the use of solid-supported Pd(0) on carbon nanotubes (Pd-
MWCNT 1-3 nm) as a highly efficient catalyst in the Suzuki cross-coupling reaction 
(Scheme 3-38).187 Coupling reactions using these solid-supported nanoparticle 
catalysts displayed remarkable catalytic activity with a high turnover number (TON 
7250) and turnover frequency (TOF 217500 h-1). The reactions generally were 
reported to be complete within 10 min, run at lower temperature (∼80 °C) using either 
conventional or microwave heating, and run in either batch or flow format. They were 
able to control the Pd(0)/Pd(II) ratio based on the method of preparation and the type 
of carbon nanotube used as the solid support.  
 
 
    Scheme 3-38. Suzuki cross-coupling catalyzed by Pd-MWCNT 
Tang et al reported the arylation of thiophenes and benzo[b]thiophenes using Pd/C as 
the catalyst under ligand-free and additive-free reaction conditions (Scheme 3-39).188 
This reaction was proved to be heterogenous in nature.  
 109 
 
 
                  Scheme 3-39. Arylation of thiophenes and benzothiophenes catalyzed by Pd on carbon 
 
Zhang et al reported ortho-directed C–C coupling reaction between 2-aryl pyridines 
and aldehydes catalyzed by palladium nanoparticles via Pd0/II/IV cycle.189 Aluminum 
oxide was used as support for palladium, and oxidant used was TBPB (Scheme 3-40).  
 
       Scheme 3-40. Arylation reactions catalyzed by Pd on aluminium oxide 
 
3.6. Scope of this dissertation 
The second project in my dissertation focuses on the C−H to C−OMe/OAc, C−Cl, C−Br 
and C−C functionalizations using solid-supported Pd(II) multi-walled carbon nanotube 
catalyst. The turn-over frequencies of solid-supported catalyst were higher than the 
reported homogenous catalyst.  
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4. C-H Halogenation and Alkoxylation reactions catalyzed by Pd(II)-MWCNT 
Catalyst 
 
We wished to test the hypothesis that a solid-supported nanoparticle catalyst 
containing predominantly Pd(II) can be used to catalyze oxidative N-chelation-directed 
C−H activation reactions that undergo the Pd(II)/Pd(IV) catalytic cycle. As the catalyst, 
we have prepared nanoparticles containing predominantly Pd(II) supported on multi-
walled carbon nanotubes (Pd(II)/MWCNT) by a modification of our previous 
procedure. We have evaluated the ability of this catalyst to carry out oxidative C−H to 
C−OMe/OAc, C−Cl, and C−Br functionalizations. 
4.1. Results and Discussion 
 
We initially chose substrates that have been previously reported to undergo the C−H 
functionalization reactions so that we could compare the results of our solid-supported 
Pd(II)/MWCNT catalyst to that of the known homogeneous Pd(II) system (Pd(OAc)2). 
We first explored the C−H to C−O transformation, which utilizes PhI(OAc)2 as the 
oxidant (Table 4-1).  
Treatment of 8-methylquinoline with Pd(II)/ MWCNT and PhI(OAc)2 in acetic acid at 
120 °C for 10 min (Table 4-1, entry 1) afforded the desired 8-(acetoxymethyl)-quinoline 
in 90% yield, comparable to the previously reported yield of 88% with the 
homogeneous catalyst. However, treatment of benzo[h]quinoline (entry 2) and 2-
phenylpyridine (entry 3) failed to give any of the desired acylation products, even at 
extended reaction times and higher temperatures. Only starting material was 
recovered in these reactions. Having confirmed that solid-supported Pd(II)/MWCNT 
can catalyze a reaction that undergoes the Pd(II)/Pd(IV) catalytic cycle and 
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encouraged by the initial success of the acylation reaction with 8-methylquinoline, we 
elected to evaluate whether other oxygen containing functional groups could be 
installed using our catalyst. We repeated the reaction of 8-methylquinoline with 
Pd(II)/MWCNT and PhI(OAc)2, except this time using methanol as a solvent (Table 4-
1, entry 4). We obtained a near-quantitative yield (99%) of the desired 8-
(methoxymethyl)quinoline in 10 min at 100 °C, which is a significant improvement over 
the reported yield of 77% with the homogeneous catalyst system. Application of these 
conditions to benzo[h]quinoline (entry 5) afforded a 90% yield of product, again 
comparable to the reported yield with the homogeneous catalyst (95%). Finally, 
treatment of 2-phenylpyridine with Pd(II)/MWCNT/PhI(OAc)2/MeOH (entry 6) did result 
in formation of the product after an extended reaction time, albeit in much lower yield 
(25%).  
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Table 4-1. C-H to C-O functionalizations catalyzed by Pd(II)-MWCNT 
 
  Solid-Supported 
Pd(II)/MWCNT 
Yield and 
time with 
Pd(OAc)2b 
Entrya Product Temp Time Yield 
 
1 
 
120 °C 0.2 h 90% 
88%, 
22 h 
 
2 
 
120 °C 1 h 0% 
86%, 
12 h 
 
3 
 
120 °C 1 h 0% 
52%, 
12 h 
  
4 
 
100 °C 0.2 h 99% 
77%, 
18 h 
 
5 
 
100 °C 0.2 h 90% 
95%, 
22 h 
 
6 
 
100 °C 5 h 25% −c 
                     a. Solvent for entries 1-3: AcOH; entries 4-6: MeOH. b. Previous reported results with 
homogeneous Pd(OAc)2; c. Yield with homogeneous Pd catalyst has not been reported. 
 
We next sought to determine whether alcohols other than methanol could be installed 
in substrates using the solid supported catalyst. Treatment of benzo[h]quinoline with 
Pd(II)/MWCNT and PhI(OAc)2 in alcohol solvents (Table 4-2) demonstrated that 
methoxy (from methanol, entry 1) and ethoxy (from ethanol, entry 2) functional groups 
can be installed in moderate to high yields with our catalyst. However, as the size of 
the alcohol increased, incorporation of the functional group into the product decreased 
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(with isopropyl, entry 3) and eventually failed (in the tert-butyl case, entry 4). Previously 
reported data for the homogeneous catalyst system show only a moderate decrease 
in yield as the size of the alcohol increases.  
Table 4-2. Steric Trend in C-H to C-O Alkyl Functionalizations Catalyzed by Pd(II)/MWCNT 
 
Entry             ROH                    Product     Yield 
Pd-MWCNT    Pd(OAc)2 
 
1 
MeOH 
 
     90% 95% 
2 
EtOH 
 
     73% 80% 
3 
iPrOH 
 
     33% 72% 
4 
tBuOH 
 
     0% −a 
        a. Yield with homogeneous Pd catalyst has not been reported. 
 
Having demonstrated that solid-supported Pd(II)/MWCNT can catalyze the C−H to 
C−O functionalization reaction, we next turned our attention to halogenation reactions 
(Table 4-3). Treatment of benzo[h]quinoline with Pd(II)/MWCNT and N-
chlorosuccinimide (NCS) in acetonitrile at 100 °C for 5 h (Table 4-3, entry 1) afforded 
the desired 10-chlorobenzo[h]quinoline in 92% yield, comparable to the previously 
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reported yield of 95% with the homogeneous catalyst. It should be noted that the 
reaction with the Pd(II)/MWCNT is much faster than with homogeneous Pd(OAc)2 (5 
h vs 3 days).  
Chlorination of (E)-3,4-dihydronaphthalen-1-(2H)-one O-methyloxime (entry 2), 2-
phenylpyridine (entry 3), and 3-methyl-2-phenylpyridine (entry 4) in either acetic acid 
(entries 2 and 4) or acetonitrile (entry 3) all afforded the desired chlorinated products 
in moderate yields in reaction times from 10 min to 6 h. While the yields for these 
transformations are lower than those for the comparable reaction with the 
homogeneous catalyst, the reaction times are much shorter, pointing to faster reaction 
kinetics (vide infra). The 2-phenylpyridine substrates (entries 3 and 4) required 
additional catalyst loading to reach this level of conversion and product isolation. For 
all of these substrates, further increasing the number of equivalents of NCS led to the 
formation of other products. 
Turning to the C−H to C−Br functionalizations, treatment of benzo[h]quinoline with 
Pd(II)/MWCNT and N-bromosuccinimide (NBS) in acetonitrile at 100 °C for 1.5 h 
(Table 4-3, entry 5) afforded the desired 10-bromobenzo[h]quinoline in 89% yield, 
comparable to the previously reported yield of 93% with the homogeneous catalyst. 
Again, it should be noted that the reaction with the Pd(II)/MWCNT is much faster than 
that with homogeneous Pd(OAc)2 (1.5 h vs 1.5 days). Bromination of (E)-3,4-
dihydronaphthalen-1-(2H)-one O-methyloxime (entry 6), 2-phenylpyridine (entry 7), 
and 3-methyl-2-phenylpyridine (entry 8) in either acetic acid (entries 6 and 8) or 
acetonitrile (entry 7) all afforded the desired brominated products in moderate yields 
in reaction times of 5−6 h. Again, the yields are lower than the comparable reaction 
with homogeneous catalyst but the reaction times are much shorter, pointing to faster 
reaction kinetics (vide infra). 
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Table 4-3. C-H to C-Cl/C-Br Functionalizations Catalyzed by Pd(II)/MWCNT 
 
    
  Solid-Supported Pd(II)/MWCNT Yield and 
time with 
Pd(OAc)2 Entrya,b Product Temp  Time Yield 
 
1 
 
 
 
100 °C 
 
 
5 h 
 
92% 
95%, 
3 days 
 
2 
 
 
120 °C 
 
1.5 h 
 
61% 88%, 
12 h 
 
3 
 
 
100 °C 6 h 55%c −e 
 
4 
 
 
 
120 °C 0.2 h 50%
c 
65%, 
12 h 
 
5 
 
 
 
100 °C 
 
 
1.5 h 
   89%d 
93%, 
1.5 days 
 
6 
 
 
120 °C 
 
5 h 
 
30% 62%, 
12 h 
7 
 
 
100 °C 6 h 40%d 
63%, 
12 h 
8 
 
 
 
120 °C 5 h 51%
c 
56%,  
12 h 
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a. Oxidants for entries 1-4: NCS; entries 5-8: NBS. b. Solvents for entries 1, 3, 5, and 7: MeCN; 
entries 2, 4, 6, and 8: AcOH. c. 10 mol% Pd(II)/MWCNT was used. d. 1.5 eq of NBS was used. e. A 
directly analogous yield for the homogeneous catalyst has not been reported. 
  
Both the benzo[h]quinoline and 2-phenylpyridine substrates (entries 5 and 7) required 
additional NBS (1.5 equiv vs 1.2 equiv) to reach this level of conversion and product 
isolation. Increasing the amount of NBS beyond 1.5 equiv led to the formation of other 
products. For the 3-methyl-2-phenylpyridine (entry 8), additional catalyst loading was 
required to reach this level of conversion and product isolation.  
 
To characterize the solid-supported Pd(II)/MWCNT catalyst, we measured the 
composition of the palladium both before and after C−H activation reaction by X-ray 
photon spectroscopy (XPS, Figure 4-1). Prior to use in the C−H activation reactions, 
the solid-supported catalyst was found to be a mixture of Pd(II) (76.54%) and Pd(0) 
(23.46%), with Pd(II) being the predominant component. After the C−H to C−OMe 
functionalization of benzo[h]quinoline (Table 4-1, entry 5), XPS showed that the solid-
supported catalyst contained only Pd(II), showing that all of the Pd(0) in the catalyst 
prior to the reaction is converted to Pd(II), and supporting the mechanism that these 
reactions use Pd(II) as the starting oxidation state. 
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Figure 4-1. Pd(II) and Pd(0) content in Pd(II)/MWCNT (a.) before and (b.) after a C-H Activation 
Reaction as measured by XPS 
To demonstrate the ability of the Pd(II)/MWCNT catalyst to be recycled, we ran the 
C−H to C−OMe functionalization on 8-methylquinoline (Table 4-1, entry 4), recovered 
the catalyst by centrifugation, and iteratively repeated the reaction with the same batch 
of catalyst. We were able to recycle the catalyst a remarkable 16 times with minimal 
reduction in yield and no catalyst deactivation (Table 4-4). We terminated the 
experiment after 16 recycles and have yet to determine the limits of the recyclability of 
the catalyst. These data demonstrate that there must be good retention or highly 
efficient leaching/redeposition of Pd in these reactions. Otherwise, leaching would 
result in loss of catalytic activity after multiple recycles. 
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                          Table 4-4. Recycling experiments with Pd(II)/MWCNT 
 
Run Conversion (%)a 
1 98 
2 98 
3 92 
4 90 
5 90 
6 90 
7 90 
8 90 
9 89 
10 90 
11 90 
12 90 
13 90 
14 90 
15 90 
16 90 
17 90 
 
a. Conversion was determined by GC/MS based upon the consumption of the starting material 
 
For all of the C−H activation reactions, we observed that the reactions catalyzed by 
Pd(II)/MWCNT seemed to be faster than those with the homogeneous Pd(OAc)2. To 
quantify this observation, we calculated turnover frequencies (TOFs) for one example 
reaction of each functionalization with both the solid-supported Pd(II)/ MWCNT and 
homogeneous palladium catalysts (Table 4-5). For the C−H to C−OAc and C−OMe 
functionalization reactions, the turnover frequencies for the solid-supported 
Pd(II)/MWCNT catalyst were ∼27-fold higher than that for the homogeneous catalyst. 
For the C−H to C−Cl and C−Br reactions, the turnover frequencies for the solid-
supported Pd(II)/MWCNT catalyst were ∼4-fold higher. This represents a significant 
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improvement over previously reported results, particularly with regard to the C−H to 
C−OMe functionalization reactions.  
 
Table 4-5. Comparison of Turn Over Frequencies in C-H to C-OAc, C-OMe, C-Cl, and C-Br Reactions 
Catalyzed by Solid-Supported Pd(II)/MWCNT and Homogeneous Pd(OAc)2 
                                            Turn Over Frequency (h-1) 
  Entry Product Pd(II)/MWCNT Pd(OAc)2 Fold-increase 
1 
 
    106.44     4.02      26.48 
2 
 
    106.94     3.79     28.22 
3 
 
     3.60    0.73     4.90 
4 
 
    9.96 2.63    3.75 
 
To determine whether the palladium metal from the solid supported Pd(II)/MWCNT 
catalyst leached into the C−H activation reactions and contaminated the products, we 
removed the catalyst by filtration over Celite from a C−H to C−OMe functionalization 
reaction on benzo[h]quinolone (Table 4-1, entry 5) and measured the palladium 
content in solution by ICP-MS. The palladium content of the reaction mixture was 
found to be <250 ppb, demonstrating that very little metal leached into the reaction 
medium. Combined with the ease of removing the catalyst from the reaction mixtures, 
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this low level of palladium in the reaction mixture is an improvement on the existing 
homogeneous catalyst for N-chelation-directed C−H activation reactions. 
 
To demonstrate that the trace palladium in the reaction mixture is not the source of 
catalytic activity, a hot filtration experiment was performed with benzo[h]quinoline 
(Table 4-1, entry 5). After 10 min at 100 °C, the Pd(II)/MWCNT catalyst was removed 
by hot filtration over Celite. Fresh substrate and oxidant were added to the filtrate, 
which was reheated to 100°C. No further conversion to product or catalytic activity was 
observed in the filtrate in the absence of Pd(II)/MWCNT, showing that the <250 ppb of 
residual Pd that remains in solution is not adequate to catalyze the C−H activation 
reaction. 
 
In conclusion, we have demonstrated that solid-supported Pd(II)/MWCNT can 
catalyze N-chelation-directed C−H to C−OAc, C−OMe, C−Cl, and C−Br activation 
reactions. For all of the C−H activation reactions examined, the solid supported 
catalyst demonstrated consistently higher turnover frequencies than the reported 
homogeneous catalyst. The solid supported Pd(II)/MWCNT also offers the advantages 
of ease of removal by filtration and low levels of residual palladium metal 
contamination in the products. We are currently working to optimize the reactions 
reported here as well as apply this catalyst to other N-chelation-directed C−H 
activation reactions. 
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Challenges faced in methoxylation reaction: 
In order to apply the methoxylation reaction in pharmaceutically relevant compounds, 
we tried the methoxylation reaction on Imatinib, which is a tyrosine-kinase inhibitor 
used in the treatment of cancers (chronic myeloid leukaemia). Unfortunately, this 
reaction gave a mixture of products (seen as a single spot on TLC 5% MeOH-DCM) 
which could not be separated (Scheme 4-1). The presence of multiple nitrogen atoms 
(directing groups) might have resulted in the methoxylation at various positions. This 
reaction needs to be further optimized to give a single product.  
 
Scheme 4-1. Methoxylation on Imatinib catalyzed by Pd-MWCNT 
 
Challenges faced in fluorination and trifluoromethylation reactions: 
First, we tried the fluorination reaction on 8-methylquinoline using the electrophilic 
fluorinating agent 1-Fluoro-2,4,6-trimethylpyridinium tetrafluoroborate (Scheme 4-2). 
The reaction did not yield any product even after various optimization attempts. This 
was not very surprising as fluorinating reactions are usually very difficult. The reported 
fluorination reactions using homogenous Pd catalysts use microwave heating to get 
the reactions to work. This shows that these reactions are thermodynamically difficult 
to achieve.  
The next step is to try using nucleophilic fluorinating agents.  
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Scheme 4-2. Fluorination on 8-methylquinoline catalyzed by Pd-MWCNT 
 
We next tried a trifluoromethylation reaction on 2-phenylpyridine (Scheme 4-3). A 
homogenous catalyst has been reported to give a yield of 44% using 
(trifluoromethyl)dibenzothiophenium tetrafluoroborate as the trifluoromethylating 
reagent. We were able to get only 22% yield when we reproduced this reaction. 
Unfortunately, when we tried the reaction with Pd-MWCNT catalyst, we were unable 
to get any product. 
 
Scheme 4-3. Trifluoromethylation on 2-phenylpyridine catalyzed by Pd-MWCNT 
 
We then tried the reaction on a different substrate – 8-methylquinoline to see if an sp3 
carbon would undergo trifluoromethylation with our Pd-MWCNT catalyst (Scheme 4-
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4). This reaction did not afford any product. As this reaction utilizes Cu(OAc)2, we also 
tried Pd-Cu nanocatalyst to see if the combined nanocatalyst would catalyze the 
reaction. Unfortunately, we did not observe any formation of product.  
 
       Scheme 4-4. Trifluoromethylation on 8-methylquinoline catalyzed by Pd-MWCNT 
These fluorination and trifluoromethylation reactions need to be further optimized in 
order to make them work. At present, the Pd-MWCNT catalyst does not appear to be 
a good catalyst for these reactions. Microwave heating of reactions and/or use of other 
solid-supported catalyst systems would be the next step in this direction. 
4.2. Experimental Procedures 
General Chemical Methods 
All the reactions were carried out in vials sealed with Teflon lined caps under ambient 
atmosphere. Palladium (II) acetate (98% reagent grade) and multi-walled carbon 
nanotubes (cat. #: 724769) were purchased from Sigma-Aldrich. Benzo[h]quinoline 
and 3-methyl-2-phenylpyridine were purchased from TCI, 2-phenylpyridine was 
purchased from Chem-Impex. All solvents were purchased from VWR and other 
chemicals were purchased from Sigma-Aldrich and all were used without distillation or 
purification. Analytical Thin Layer Chromatography (TLC) was performed using silica 
gel GHLF plates (Analtech Inc., DE, USA). Flash chromatography was performed on 
TELEDYNE ISCO CombiFlash® Rf instrument using RediSep Rf Normal-phase Flash 
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Columns (4-gm, 12-gm, 24-gm or 40-gm). NMR spectra were recorded on a Bruker 
400 MHz instrument operating at 400 MHz for 1H and 125 MHz for 13C acquisitions. 
Electrospray ionization (ESI) mass spectra were obtained from Perkin Elmer Flexar 
UPLC/AxION2 TOF Mass Spectrometer. The X-ray photoelectron spectroscopy (XPS) 
analysis was performed on a Thermo Fisher Scientific ESCALAB 250 using a 
monochromatic Al KR X-ray. The Pd content in the Pd nanoparticles supported on 
carbon nanotubes before and after reaction was determined using an Inductively 
Coupled Plasma equipped with Mass Spectrometry (ICP-MS, Varian 820-MS). 
  
Synthesis of Pd(II) nanoparticles on Multi-Walled Carbon Nanotubes Catalyst 
[Pd(II)/MWCNT]. 
Palladium (II) acetate (0.103 g, 4.6 mmol) and multi-walled carbon nanotubes (0.500 
g) were loaded in a 45 ml zirconia grinding vial. Two 12.77 mm diameter zirconia balls 
are also placed in the vial before sealing.  The container is then placed in an 8000 M 
Spex Mixer/Mill.  The contents in the mixer were shaken back and forth 5.9 cm and 
side-to-side 2.5 cm for 10 minutes at room temperature at 115 volts (1060 
cycles/minute).  The resulting solid was collected and used directly in reactions. 
NOTE: The shorter ball-milling time (10 minutes vs. 30 minutes used in the original 
method) resulted in a higher Pd(II)/Pd(0) ratio (76.54% Pd(II), 23.46% Pd(0)). 
  
Quinolin-8-ylmethyl acetate (1) 
 
PhI(OAc)2 (89 mg, 0.28 mmol) and Pd-MWCNT (7 mg, 5 mol%) were added to a 
solution of 8-methylquinoline (20 mg, 0.14 mmol) in AcOH (1.2 mL). The reaction was 
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heated at 120 oC for 10 min.  After cooling to room temperature, it was diluted with 
EtOAc and washed with brine. The organic layer was filtered through celite, Na2SO4 
and dried. The crude product was purified by flash chromatography (silica gel, 20% 
EtOAc/n-hexane) to give the product as a white solid (25 mg) in 90% yield. Analytical 
data (1H NMR, 13C NMR, mass spec) matched the previously reported data. 
 
8-(Methoxymethyl)quinoline (4) 
 
PhI(OAc)2 (89 mg, 0.28 mmol) and Pd-MWCNT (7 mg, 5 mol%) were added to a 
solution of 8-methylquinoline (20 mg, 0.14 mmol) in methanol (1.2 mL). The reaction 
was heated at 100 oC for 10 min.  After cooling to room temperature, it was diluted 
with EtOAc, filtered through celite, Na2SO4 and dried. The crude product was purified 
by flash chromatography (silica gel, 20% EtOAc/n-hexane) to give the product as 
yellow oil (24 mg) in 99% yield. Analytical data (1H NMR, 13C NMR, mass spec) 
matched the previously reported data. 
 
10-Methoxybenzo[h]quinoline (5) 
 
PhI(OAc)2 (89 mg, 0.28 mmol) and Pd-MWCNT (7 mg, 5 mol%) were added to a 
solution of benzo[h]quinoline (25 mg, 0.14 mmol) in methanol (1.2 mL). The reaction 
was heated at 100 oC for 10 min.  After cooling to room temperature, it was diluted 
with EtOAc, filtered through celite, Na2SO4 and dried. The crude product was purified 
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by flash chromatography (silica gel, 5% MeOH/DCM) to give the product as a pale 
yellow solid (26 mg) in 90% yield. Analytical data (1H NMR, 13C NMR, mass spec) 
matched the previously reported data. 
 
2-(2-Methoxyphenyl)pyridine (6) 
 
PhI(OAc)2 (87 mg, 0.27 mmol) and Pd-MWCNT (10 mg, 5 mol%) were added to a 
solution of 2-phenylpyridine (30 mg, 0.19 mmol) in methanol (1.6 mL). The reaction 
was heated at 100 oC for 5 h.  After cooling to room temperature, it was diluted with 
EtOAc, filtered through celite, Na2SO4 and dried. The crude product was purified by 
flash chromatography (silica gel, 20% EtOAc/n-hexane) to give the product as a clear 
liquid (9 mg) in 25% yield. Analytical data (1H NMR, 13C NMR, mass spec) matched 
the previously reported data. 
 
10-Ethoxybenzo[h]quinoline (7) 
 
PhI(OAc)2 (89 mg, 0.28 mmol) and Pd-MWCNT (7 mg, 5 mol%) were added to a 
solution of benzo[h]quinoline (25 mg, 0.14 mmol) in ethanol (1.2 mL). The reaction 
was heated at 100 oC for 10 min.  After cooling to room temperature, it was diluted 
with EtOAc, filtered through celite, Na2SO4 and dried. The crude product was purified 
by flash chromatography (silica gel, 5% MeOH/DCM) to give the product as thick oil 
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(22.6 mg) in 73% yield. Analytical data (1H NMR, 13C NMR, mass spec) matched the 
previously reported data. 
 
10-Isopropoxybenzo[h]quinoline (8) 
 
PhI(OAc)2 (89 mg, 0.28 mmol) and Pd-MWCNT (7 mg, 5 mol%) were added to a 
solution of benzo[h]quinoline (25 mg, 0.14 mmol) in isopropanol (1.2 mL). The reaction 
was heated at 100 oC for 3 h.  After cooling to room temperature, it was diluted with 
EtOAc, filtered through celite, Na2SO4 and dried. The crude product was purified by 
flash chromatography (silica gel, 5% MeOH/DCM) to give the product as brown oil (11 
mg) in 33% yield. Analytical data (1H NMR, 13C NMR, mass spec) matched the 
previously reported data. 
 
10-Chlorobenzo[h]quinoline (10) 
 
NCS (21 mg, 0.16 mmol) and Pd-MWCNT (7 mg, 5 mol%) were added to a solution 
of benzo[h]quinoline (25 mg, 0.14 mmol) in ACN (1.2 mL). The reaction was heated at 
100 oC for 5 h.  After cooling to room temperature, it was diluted with EtOAc, filtered 
through celite, Na2SO4 and dried. The crude product was purified by flash 
chromatography (silica gel, 10% EtOAc/n-hexane) to give the product as a white solid 
(27 mg) in 92% yield. Analytical data (1H NMR, 13C NMR, mass spec) matched the 
previously reported data. 
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(E)-8-Chloro-3,4-dihydronaphthalen-1(2H)-one O-methyl oxime (11) 
 
NCS (24 mg, 0.18 mmol) and Pd-MWCNT (9 mg, 5 mol%) were added to a solution 
of (E)-3,4-dihydronaphthalen-1(2H)-one O-methyl oxime (30 mg, 0.17 mmol) in AcOH 
(1.4 mL). The reaction was heated at 120 oC for 1.5 h.  After cooling to room 
temperature, it was diluted with EtOAc, washed with brine. The organic layer was 
filtered through celite, Na2SO4 and dried. The crude product was purified by flash 
chromatography (silica gel, 5% EtOAc/n-hexane) to give the product as clear oil (22 
mg) in 61% yield. Analytical data (1H NMR, 13C NMR, mass spec) matched the 
previously reported data. 
 
2-(2-Chlorophenyl)pyridine (12) 
 
NCS (26 mg, 0.19 mmol) and Pd-MWCNT (17 mg, 10 mol%) were added to a solution 
of 2-phenylpyridine (25 mg, 0.16 mmol) in ACN (1.3 mL). The reaction was heated at 
100 oC for 6 h.  After cooling to room temperature, it was diluted with EtOAc, filtered 
through celite, Na2SO4 and dried. The crude product was purified by flash 
chromatography (silica gel, 10% EtOAc/n-hexane) to give the product as a clear liquid 
(16.7 mg) in 55% yield. Analytical data (1H NMR, 13C NMR, mass spec) matched the 
previously reported data. 
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2-(2-Chlorophenyl)-3-methylpyridine (13) 
 
NCS (28 mg, 0.21 mmol) and Pd-MWCNT (19 mg, 10 mol%) were added to a solution 
of 3-methyl-2-phenylpyridine (30 mg, 0.18 mmol) in AcOH (1.5 mL). The reaction was 
heated at 120 oC for 10 min.  After cooling to room temperature, it was diluted with 
EtOAc, washed with brine. The organic layer was filtered through celite, Na2SO4 and 
dried. The crude product was purified by flash chromatography (silica gel, 10% 
EtOAc/n-hexane) to give the product as clear oil (18 mg) in 50% yield. Analytical data 
(1H NMR, 13C NMR, mass spec) matched the previously reported data. 
 
10-Bromobenzo[h]quinoline (14) 
 
NBS (37 mg, 0.21 mmol) and Pd-MWCNT (7 mg, 5 mol%) were added to a solution of 
benzo[h]quinoline (25 mg, 0.14 mmol) in ACN (1.2 mL). The reaction was heated at 
100 oC for 1.5 h.  After cooling to room temperature, it was diluted with EtOAc, filtered 
through celite, Na2SO4 and dried. The crude product was purified by flash 
chromatography (silica gel, 10% EtOAc/n-hexane) to give the product as a white solid 
(27 mg) in 89% yield. Analytical data (1H NMR, 13C NMR, mass spec) matched the 
previously reported data. 
 
 
 
 130 
 
(E)-8-Bromo-3,4-dihydronaphthalen-1(2H)-one O-methyl oxime (15) 
 
NBS (106 mg, 0.60 mmol) and Pd-MWCNT (30 mg, 5 mol%) were added to a solution 
of (E)-3,4-dihydronaphthalen-1(2H)-one O-methyl oxime (100 mg, 0.57 mmol) in 
AcOH (4.7 mL). The reaction was heated at 120 oC for 5 h.  After cooling to room 
temperature, it was diluted with EtOAc, washed with brine. The organic layer was 
filtered through celite, Na2SO4 and dried. The crude product was purified by flash 
chromatography (silica gel, 5% EtOAc/n-hexane) to give the product as yellow oil (43 
mg) in 30% yield. Analytical data (1H NMR, 13C NMR, mass spec) matched the 
previously reported data. 
 
2-(2-Bromophenyl)pyridine (16) 
 
NBS (43 mg, 0.24 mmol) and Pd-MWCNT (8 mg, 5 mol%) were added to a solution of 
2-phenylpyridine (25 mg, 0.16 mmol) in ACN (1.3 mL). The reaction was heated at 
100 oC for 6 h.  After cooling to room temperature, it was diluted with EtOAc, filtered 
through celite, Na2SO4 and dried. The crude product was purified by flash 
chromatography (silica gel, 10% EtOAc/n-hexane) to give the product as yellow oil 
(15.1 mg) in 40% yield. Analytical data (1H NMR, 13C NMR, mass spec) matched the 
previously reported data. 
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2-(2-Bromophenyl)-3-methylpyridine (17) 
 
NBS (38 mg, 0.21 mmol) and Pd-MWCNT (19 mg, 10 mol%) were added to a solution 
of 3-methyl-2-phenylpyridine (30 mg, 0.18 mmol) in AcOH (1.5 mL). The reaction was 
heated at 120 oC for 10 min.  After cooling to room temperature, it was diluted with 
EtOAc, washed with brine. The organic layer was filtered through celite, Na2SO4 and 
dried. The crude product was purified by flash chromatography (silica gel, 10% 
EtOAc/n-hexane) to give the product as clear oil (22.3 mg) in 51% yield. Analytical 
data (1H NMR, 13C NMR, mass spec) matched the previously reported data.  
 
Procedure for Recycling Experiment. 
To a solution of 8-methylquinoline (20 mg, 0.14 mmol) in methanol (1.2 mL) in 10 mL 
reaction vial, was added PhI(OAc)2 (89 mg, 0.28 mmol) and Pd(II)/MWCNT (7 mg, 5 
mol%).  The vial was sealed and the reaction mixture was heated at 100 °C for 10 min.  
Upon the completion of the reaction period, the mixture was diluted with 2 mL methanol 
and shaken. The entire mixture was centrifuged and the solvent above the Pd/MWCNT 
nanoparticles was decanted.  The washing and centrifugation were repeated for two 
additional times to ensure the removal of the organic products from the surface of the 
catalyst. The Pd/MWCNT nanoparticles was then reused for the subsequent reaction 
using fresh reagents (8-methylquinoline, PhI(OAc)2, and methanol). This procedure 
was applied for every recycling experiment and the percent conversion to the products 
was determined by means of GC-MS spectroscopy  
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Procedure for Hot filtration Experiment. 
Benzo[h]quinoline (25 mg, 0.14 mmol) in methanol (1.2 mL) was heated in the 
presence of Pd(II)/MWCNT (7 mg, 5 mol%) and PhI(OAc)2 (89 mg, 0.28 mmol) in a 10 
mL reaction vial at 100 °C for 10 min, resulting in 95% conversion to the product 
according to the GC-MS analysis. The reaction mixture was then hot filtered over celite 
and the filtrate solution was subjected to ICP-MS in which the amount of Pd content 
was determined to be <250 ppb. Fresh reagents (Benzo[h]quinoline (25 mg, 0.14 
mmol), and PhI(OAc)2 (89 mg, 0.28 mmol)) were added to the filtrate solution, the 
mixture was heated at 100 °C for additional 10 min.  No further catalytic activity was 
observed in this mixture by GC-MS spectroscopy. 
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5. C-H Arylation Reactions Catalyzed by our Solid-Supported Pd(II)-
MWCNT Catalyst 
 
This chapter discusses C–H arylation reactions that were catalyzed by our Pd(II)-
MWCNT catalyst.  
 
5.1. Results and Discussion  
 
Initially, we carried out reactions on the substrates that have already been reported to 
undergo N-chelation-directed C–H arylation reactions, so that we could compare the 
results with homogenous catalyst Pd(OAc)2 (Table 5-1). First, we tried arylation 
reactions on 2-phenyl-3-methylpyridine (entry 1) using the symmetrical arylating agent 
[Ph2I]BF4. Reaction was carried out at 100oC, using 5 mol% of Pd (II)-MWCNT catalyst 
in the presence of solvent acetic-acid. We were pleased to find that the reaction was 
complete in 12 hours, and gave a yield of 90%. The turn-over frequency of this reaction 
was comparable to that reported for the homogenous palladium catalysed reaction. 
Motivated by this result, we carried out the same reaction on various substrates. There 
was a single isomeric product formed in entry 2, which suggests that this C-H arylation 
is dictated by steric factors, instead of dual chelation effects of Pd and ketone. In 
entries 3 and 4, where the substrates have amide type of nitrogen, the yields were 
very low – 27% and 32% respectively. This could be because the lone pair of electrons 
on amide nitrogen are not readily available, hence Pd chelation might be the rate 
limiting step. These reactions had lower TOFs than the homogenous Pd catalyst. The 
arylation reaction on benzo[h]quinoline (entry 5) gave the product albeit in low yield of 
19%. 
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Table 5-1. C-H to C-C Functionalizations Catalyzed by Pd(II)/MWCNT 
 
 
 
Entry 
   
 
    Product 
 
Yield and time 
with Pd(II)/MWCNT 
Yield and 
time with 
Pd(OAc)2 
 
1 
 
 
 
 
 
 
90%, 12 h 
 
88%, 12 h 
 
2b 
  
80%, 24 h 
 
91%, 48 h 
 
3c 
  
27%, 12h 
 
49%, 12h 
 
4 
  
32%, 24 h 
 
75%, 24 h 
 
5 
  
19%, 12 h 
 
NRd 
a. Entries 1, 4, 5: [Ph2I]BF4 1.2 eq. b. [Ph2I]BF4 1.5 eq. c. [Ph2I]BF4 2 eq, solvent AcOH:Ac2O 
(1:1). d. not reported under similar conditions 
 
 
We next wished to expand the scope of our transformations to incorporate other aryl 
rings (Table 5-2). In order to selectively transfer a specific aryl ring, we used 
asymmetrical arylating agents [Mes-I-Ar] as reported by Sanford et al.139 The 
asymmetrical arylating agents consist of a mesitylene group (which cannot be 
transferred due to its high bulk) and a substituted aryl group (which would get 
transferred selectively). Both electronically neutral aryl methyl group (entry 1) and 
electronically poor aryl fluoro group (entry 2) were transferred with good yields (87% 
and 79% respectively) with reaction rates almost equal to that of the homogenous 
catalyst. In contrast, the electronically rich aryl methoxy group (entry 3) did not react 
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very well, with a yield of only 33%. Increasing the reaction time did not improve the 
yield. This is in contrast to the homogenous catalyst which has been reported to have 
a yield of 81%. This effect was not seen in the ethoxy aryl group (entry 8), where the 
reaction gave a yield of 79%. The reason for this difference in the reactivity of methoxy-
and ethoxy-substituted substrates is currently unknown.  
 
We then carried out arylations that have not been reported yet with homogenous Pd 
catalyst. With the electron withdrawing nitro group, para/meta/ortho substitution 
position did not have any influence on the reaction. All three positions gave almost 
similar yields (entries 4-6). These transformations are significant as the products in 
entries 4 and 6 have not been reported to date. Thus, C-H arylation through 
Pd(II)/Pd(IV) can be used to give products that are not obtained through conventional 
coupling reactions.  
 
In the case of aryl aldehyde, the ortho substituent gave a poor yield of 18% (entry 7), 
whereas the para substituent gave a good yield of 77% (entry 9). The huge difference 
between the reactivities of ortho nitro (entry 6) and ortho aldehyde (entry 7) could be 
explained by the difference in electronic nature of both the substituents. Nitro group is 
a much stronger electron withdrawing group compared to aldehyde. So, the nitro group 
makes the aryl ring highly reactive towards oxidative addition of Pd (II) to Pd (IV). 
Though it is in ortho position, the electronics might be dictating the reaction compared 
to sterics, which explains higher yield of the reaction. Whereas with ortho aldehyde, 
as it is not a strong electron withdrawing group, the sterics might be dictating the 
reaction, which explains lower yield.  
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Table 5-2. C-H to C-C Functionalizations Catalyzed by Pd(II)/MWCNT on 3-methyl-2-phenylpyridine 
 
 
 
 
Entry 
    
       
        Product 
 
Yield and time  
with Pd(II)/MWCNT                                
 
Yield and time  
with Pd(OAc)2 
 
1 
  
87%, 12 h 
 
84%, 12 h 
 
2 
  
79%, 12 h 
 
88%, 12 h 
 
3 
  
33%, 12h 
 
81%, 12 h 
 
4 
  
61%, 12 h 
 
NRa 
 
5 
  
69%, 12 h 
 
NRa 
 
6 
  
58%, 12 h 
 
NRa 
 
7 
  
18%, 12 h 
 
NRa 
 
8 
  
79%, 12 h 
 
NRa 
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9 
  
77%, 12 h 
 
NRa 
 
     a. not reported under similar conditions 
 
 
We wished to expand C-H arylation catalysed by our Pd(II)-MWCNT catalyst to a more 
rigid and bulky substrate benzo[h]quinoline (Table 5-3). We were pleased to obtain the 
arylated product (entry 1) albeit in low yield of 19%. This transformation has been 
achieved with very simple reaction conditions. This transformation has been reported 
by Sanford et al, but using different conditions (89% yield using palladium acetate, 
benzoquinone oxidant, DMSO and Ag2CO3). Though the yield with our solid-supported 
catalyst is low, it is an attractive transformation due to its simplicity.  
 
We then expanded this reaction to incorporate substituted aryl rings – electron 
withdrawing aryl fluoro group (entry 2) and electronically neutral aryl methyl group 
(entry 3). We were pleased to find that the fluoro substituent gave a yield of 35%, 
which is higher than the unsubstituted phenyl ring (entry 1). This could be due to the 
aryl ring being electron deficient due to the presence of fluoro group, thus making it 
more reactive towards oxidative addition of Pd(II) to Pd(IV). Methyl substituted aryl 
group gave a low yield of 15% (entry 3) comparable to that of unsubstituted phenyl 
ring. This type of reaction is very attractive because the products in entries 2 and 3 
have been reported but using more complicated reaction conditions and/or using 
highly expensive catalysts such as Rh. We are in the process of optimizing our reaction 
conditions to improve the yields further. 
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Table 5-3. C-H to C-C Functionalizations Catalyzed by Pd(II)/MWCNT on benzo[h]quinoline 
 
Entry        Product Yield and time  
with Pd(II)/MWCNT                                
Yield and time with 
Pd(OAc)2
 
1 
  
19%, 12 h 
 
NRa 
 
2 
  
35%, 12 h 
 
NRa 
 
3 
  
 
15%, 12h 
 
 
NRa 
a. not reported under similar conditions 
 
 
Arylation reaction challenges: 
Arylation on 8-methylquinoline using the symmetrical arylating agent gave a mixture 
of starting material and another isomer (which could not be identified, Scheme 5-1). 
The reaction did not go to completion. This mixture could not be purified on normal 
phase, so the yield of the product could not be determined. In order to optimize this 
reaction, when AcOH was used as the solvent, diarylated product was formed and the 
staring material was still not completely consumed.  
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          Scheme 5-1. C-H arylation on 8-methylquinoline 
 
Similar reaction on 2-phenylpyridine gave a mixture of product and another isomer, 
which could not be purified on normal phase. So, the yield was not calculated (Scheme 
5-2). 
 
             Scheme 5-2. C-H arylation on 2-phenylpyridine 
 
We were able to successfully synthesize asymmetrical arylating agents – 4-
bromomethyl and 2-cyano. But unfortunately, the coupling reactions of these arylating 
agents with 3-methyl-2-phenylpyridine did not afford the product (Scheme 5-3). 
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   Scheme 5-3. Challenges in C-H arylation reactions 
 
We were unable to synthesize some of the arylating reagents. The reactions to make 
4-cyano and 4-dimethylamino arylating agent did not work at all, while 3-pyridyl 
arylating reagent was formed in very low yield of 4% (Scheme 5-4). 
 
                 Scheme 5-4. Challenges in synthesis of arylating agents 
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Arylation reaction between benzo[h]quinoline and 1,2-dichlorobenzene using 
benzoquinone promoter, Ag2CO3 oxidant, Pd-MWCNT catalyst, and DMSO (to protect 
catalyst) gave the product in good yield (68%, Scheme 5-5). In contrast, when the 
reaction was tried on 1,2-dimethoxy benzene, the reaction did not work (Scheme 5-6). 
This might be because methoxy is sterically bulkier than the chloro group. Sterics 
might be dictating this reaction.   
 
 
              Scheme 5-5. Arylation of benzo[h]quinolone with 1,2-dichlorobenzene 
 
 
 
              Scheme 5-6. Arylation of benzo[h]quinolone with 1,2-dimethoxybenzene 
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5.2. Experimentals 
 
 
Diphenyliodonium tetrafluoroborate: Under nitrogen, phenylboronic acid (0.4 
mmol) was dissolved in DCM (0.1 M), cooled to 0 oC. To this, BF3OEt2 (0.4 mmol) was 
added. The reaction mixture was stirred at 0 oC for 15 min. This was followed by the 
addition of diacetoxyiodobenzene (0.4 mmol) dissolved in DCM (0.1 M) to the above 
reaction mixture. It was stirred at 0 oC for 1.5 h under nitrogen. To this, saturated 
solution of aqueous NaBF4 (1.5 mL) was added, the reaction was stirred for 30 min. 
The reaction mixture was extracted with DCM, washed with water and filtered over 
MgSO4. The organic layer was dried, washed with hexanes : DCM (3:1). The 
precipitate was collected, washed with hexanes and dried to afford pure product in 
84% yield (119.5 mg, 0.3 mmol). 1H NMR (400 MHz, (CD3)2SO) δ 8.24 (d, J = 7.56 
Hz, 4H), 7.66 (t, J = 7.45 Hz, 2H), 7.53 (t, J = 7.76 Hz, 4H); 13C NMR (125 MHz, 
(CD3)2SO) δ 135.12, 132.02, 131.73, 116.44. 
 
General procedure A for the synthesis of asymmetrical arylating agents: Under 
nitrogen, substituted phenylboronic acid (0.7 mmol) was suspended/dissolved in DCM 
(0.1 M), cooled to 0 oC. To this, BF3OEt2 (0.8 mmol) was added. The reaction mixture 
was stirred at 0 oC for 15 min. This was followed by the addition of iodomesitylene 
diacetate (0.8 mmol) dissolved in DCM (0.3 M) to the above reaction mixture. It was 
warmed to room temperature, and stirred for 2 h under nitrogen. To this, saturated 
solution of aqueous NaBF4 (3.0 mL) was added, the reaction was stirred for 30 min. 
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The reaction mixture was extracted with DCM, washed with water, filtered over 
MgSO4. Organic layer was dried, washed with Et2O to afford pure product. 
(4-fluorophenyl)(mesityl)iodonium tetrafluoroborate: General procedure A was 
followed on substrate 4-fluorophenyl boronic acid to afford the product in 75% yield 
(229.6 mg, 0.54 mmol). 1H NMR (400 MHz, (CD3)2SO) δ 8.02-8.04 (m, 2H), 7.36 (t, J 
= 8.91 Hz, 2H), 7.21 (s, 2H), 2.60 (s, 6H), 2.29 (s, 3H); 13C NMR (125 MHz, (CD3)2SO) 
δ 143.16, 141.47, 137.21, 137.12, 129.77, 122.94, 119.31, 119.08, 108.62, 30.62, 
26.22, 20.47. 
 
 
mesityl(p-tolyl)iodonium tetrafluoroborate: General procedure A was followed on 
substrate 4-tolyl boronic acid to afford the product in 70% yield (217.2 mg, 0.51 mmol). 
1H NMR (400 MHz, (CD3)2SO) δ 7.85 (d, J = 8.36 Hz, 2H), 7.30 (d, J = 8.44 Hz, 2H), 
7.20 (s, 2H), 2.59 (s, 6H), 2.32 (s, 3H), 2.29 (s, 3H); 13C NMR (125 MHz, (CD3)2SO) δ 
142.99, 142.23, 141.44, 134.43, 132.45, 129.71, 122.68, 110.83, 26.24, 20.73, 20.45. 
 
 (4-ethoxyphenyl)(mesityl)iodonium tetrafluoroborate: General procedure A was 
followed on substrate 4-ethoxyphenyl boronic acid to afford the product in 95% yield 
(142.1 mg, 0.31 mmol). 1H NMR (400 MHz, (CD3)2SO) δ 7.66 (d, J = 9.35 Hz, 2H), 
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7.26 (s, 1H), 7.09 (s, 2H), 6.91 (d, J = 9.39 Hz, 2H), 4.02 (q, J = 7.18 Hz, 6.93 Hz, 2H), 
2.65 (s, 6H), 2.35 (s, 3H), 1.39 (t, J = 6.97 Hz, 3H); 13C NMR (125 MHz, (CD3)2SO) δ 
160.99, 142.85, 141.29, 136.48, 129.64, 123.04, 117.86, 103.15, 63.75, 26.19, 20.43, 
14.30. 
 
 
(4-formylphenyl)(mesityl)iodonium tetrafluoroborate: General procedure A was 
followed on substrate 4-formylphenyl boronic acid to afford the product in 69% yield 
(101 mg, 0.23 mmol). 1H NMR (400 MHz, (CD3)2SO) δ 10.00 (s, 1H), 8.15 (d, J = 8.48 
Hz, 2H), 7.95 (d, J = 8.48 Hz, 2H), 7.24 (s, 2H), 2.60 (s, 6H), 2.30 (s, 3H); 13C NMR 
(125 MHz, (CD3)2SO) δ 192.32, 143.27, 141.58, 137.74, 134.85, 131.85, 129.83, 
122.91, 120.71, 26.24, 20.46. 
mesityl(4-methoxyphenyl)iodonium tetrafluoroborate: General procedure A was 
followed on substrate 4-methoxyphenyl boronic acid to afford the product in 85% yield 
(251.2 mg, 0.57 mmol). 1H NMR (400 MHz, (CD3)2SO) δ 7.91 (d, J = 9.1 Hz, 2H), 7.19 
(s, 2H), 7.03 (d, J = 9.25 Hz, 2H), 3.78 (s, 3H), 2.60 (s, 6H), 2.29 (s, 3H); 13C NMR 
(125 MHz, (CD3)2SO) δ 161.69, 142.83, 141.27, 136.46, 129.62, 123.01, 117.47, 
103.32, 55.63, 26.17, 20.41. 
 
 
 145 
 
mesityl(2-nitrophenyl)iodonium tetrafluoroborate: General procedure A was 
followed on substrate 2-nitrophenyl boronic acid to afford the product in 79% yield (241 
mg, 0.53 mmol). 1H NMR (400 MHz, (CD3)2SO) δ 8.59 (d, J = 8.09 Hz, 1H), 7.79-7.90 
(m, 2H), 7.41 (s, 2H), 7.03 (d, J = 8.04 Hz, 1H), 2.56 (s, 6H), 2.42 (s, 3H); 13C NMR 
(125 MHz, (CD3)2SO) δ 145.93, 144.72, 142.95, 138.08, 132.23, 130.41, 130.22, 
127.87, 120.58, 108.39, 26.15, 20.72. 
 
(2-formylphenyl)(mesityl)iodonium tetrafluoroborate: General procedure A was 
followed on substrate 2-formylphenyl boronic acid to afford the product in 30% yield 
(86 mg, 0.2 mmol. 1H NMR (400 MHz, (CD3)2SO) δ 10.32 (s, 1H), 8.43 (dd, J = 7.5 
Hz, 1H), 7.91 (td, J = 7.28 Hz, 1H), 7.79 (td, J = 7.85 Hz, 1H), 7.39 (s, 2H), 6.90 (d, J 
= 8.29 Hz, 1H), 3.32 (s, 9H), 2.42 (s, 3H); 13C NMR (125 MHz, (CD3)2SO) δ 195.04, 
144.41, 143.05, 138.48, 138.41, 132.97, 131.57, 130.05, 128.92, 116.99, 110.14, 
25.99, 20.68. 
 
mesityl(2-nitrophenyl)iodonium tetrafluoroborate: General procedure A was 
followed on substrate 3-nitrophenyl boronic acid. Product could not be isolated to get 
a pure NMR spectrum. 
 146 
 
 
mesityl(4-nitrophenyl)iodonium tetrafluoroborate: General procedure A was 
followed on substrate 4-nitrophenyl boronic acid. Product could not be isolated to get 
a pure NMR spectrum. 
 
 
General procedure B for arylation using [Ph2I]BF4: Substrate (0.05 mmol) was 
added to acetic-acid (0.12 M) followed by the addition of arylating agent [Ph2I]BF4 
(0.08 mmol) and Pd(II)-MWCNT catalyst (5 mol%). The reaction mixture was heated 
at 100 oC for 3 h. It was then cooled to room temperature, diluted with DCM, washed 
with saturated aqueous NaHCO3, brine, and filtered over celite and MgSO4. The 
organic layer was dried and purified over silica using 20% EtOAc-hexanes unless 
otherwise noted.  
 
1-(2-(pyridin-2-yl)-[1,1'-biphenyl]-4-yl)ethan-1-one: General procedure B was 
followed on substrate 1-(3-(pyridin-2-yl)phenyl)ethan-1-one to afford the product in 
80% yield (11.1 mg, 0.04 mmol). 1H NMR (400 MHz, (CD3)2CO) δ 8.60-8.62 (m, 1H), 
8.27 (d, J = 1.8 Hz, 1H), 8.10 (dd, J = 8.1Hz, 1H), 7.58 (d, J = 8.0 Hz, 1H), 7.52 (td, J 
= 7.7 Hz, 1H), 7.27-7.30 (m, 3H), 7.21-7.25 (m, 1H) 7.17-7.19 (m, 2H), 6.98 (dt, J = 
7.9 Hz, 1H), 2.66 (s, 3H); 13C NMR (125 MHz, (CD3)2CO) δ 197.49, 159.32, 150.40, 
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145.86, 141.48, 140.98, 137.27, 136.30, 131.67, 131.50, 130.25, 129.07, 128.79, 
128.22, 125.91, 122.73, 26.81. 
 
1-(7-phenylindolin-1-yl)ethan-1-one: General procedure B was followed on 
substrate 1-(indolin-1-yl)ethan-1-one, using a mixture of 1:1 CH3COOH: (CH3CO)2CO 
as the solvent, and purified using 10% acetone-EtOAc to afford the product in 27% 
yield (6 mg, 0.03 mmol). 1H NMR (400 MHz, (CD3)2CO) δ 7.38-7.48 (m, 4H), 7.16-7.31 
(m, 4H), 4.24 (t, J = 7.6 Hz, 2H), 3.04 (t, J = 7.5 Hz, 2H), 2.76 (s, 3H); 13C NMR (125 
MHz, (CD3)2CO) δ 142.25, 141.63, 137.65, 129.75, 129.64, 128.17, 127.75, 125.98, 
124.63, 51.16, 22.82. 
 
 
1-([1,1'-biphenyl]-2-yl)pyrrolidin-2-one: General procedure B was followed on 
substrate 1-phenylpyrrolidin-2-one, and purified using 10% acetone-EtOAc to afford 
the product in 32% yield (7 mg, 0.03 mmol). 1H NMR (400 MHz, (CDCl3) δ 7.31-7.42 
(m, 9H), 3.21 (t, J = 6.7 Hz, 2H), 2.41 (t, J = 7.9 Hz, 2H), 1.83-1.90 (m, 2H); 13C NMR 
(125 MHz, CDCl3) δ 175.72, 139.87, 139.36, 136.58, 131.01, 128.71, 128.56, 128.17, 
127.73, 50.35, 31.35, 29.85, 19.15. 
 2-([1,1'-biphenyl]-2-yl)-3-methylpyridine: General procedure B was followed on 
substrate 3-methyl-2-phenylpyridine, and purified using 5% EtOAc-DCM to afford the 
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product in 90% yield (19.5 mg, 0.08 mmol). 1H NMR (400 MHz, (CDCl3) δ 8.49 (dd, J 
= 4.9 Hz, 1H), 7.42-7.50 (m, 3H), 7.38-7.41 (m, 1H), 7.28-7.30 (m, 1H), 7.08-7.17 (m, 
6H), 1.76 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 159.63, 146.65, 141.28, 140.87, 
139.58, 137.64, 131.82, 130.04, 129.87, 129.43, 128.51, 127.93, 127.57, 126.78, 
122.24, 18.95. 
 
General procedure C for arylation using asymmetrical arylating agents: 
Substrate (0.05 mmol) was added to acetic-acid (0.12 M) followed by the addition of 
asymmetrical arylating agent [Mes-I-Ar]BF4 (0.08 mmol) and Pd(II)-MWCNT catalyst 
(5 mol%). The reaction mixture was heated at 100 oC for 3 h. It was then cooled to 
room temperature, diluted with DCM, washed with saturated aqueous NaHCO3, brine, 
and filtered over celite and MgSO4. The organic layer was dried and purified over silica 
using 20% EtOAc-hexanes unless otherwise noted. 
 
3-methyl-2-(4'-methyl-[1,1'-biphenyl]-2-yl)pyridine: General procedure C was 
followed on substrate 3-methyl-2-phenylpyridine, using [Mes-I-p-Me-C6H5]BF4 to 
afford the product in 87% yield (20 mg, 0.08 mmol). 1H NMR (400 MHz, (CD3)2CO) δ 
8.43 (dd, J = 4.9 Hz, 1H), 7.38-7.49 (m, 4H), 7.32-7.34 (m, 1H), 7.15 (q, 1H), 6.98-
7.03 (m, 4H), 2.66 (s, 3H), 1.74 (s, 3H); 13C NMR (125 MHz, (CD3)2CO) δ 160.66, 
147.33, 141.47, 140.83, 139.27, 138.04, 137.09, 132.10, 130.86, 130.35, 129.92, 
129.36, 129.02, 127.82, 123.02, 20.99, 19.00. 
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2-(4'-fluoro-[1,1'-biphenyl]-2-yl)-3-methylpyridine: General procedure C was 
followed on substrate 3-methyl-2-phenylpyridine, using [Mes-I-p-F-C6H5]BF4 to afford 
the product in 79% yield (18.5 mg, 0.07 mmol). 1H NMR (400 MHz, (CD3)2CO) δ 8.43 
(dd, J = 4.99 Hz, 1H), 7.42-7.52 (m, 4H), 7.34-7.37 (m, 1H), 7.13-7.19 (m, 3H), 6.92-
6.97 (m, 2H), 1.78 (s, 3H), 1.74 (s, 3H); 13C NMR (125 MHz, (CD3)2CO) δ 163.94, 
161.51, 160.26, 147.40, 140.88, 140.50, 138.43, 138.22, 132.12, 131.96, 131.88, 
130.86, 130.39, 129.14, 128.23, 123.17, 115.51, 115.30, 18.97. 
2-(4'-ethoxy-[1,1'-biphenyl]-2-yl)-3-methylpyridine: General procedure C was 
followed on substrate 3-methyl-2-phenylpyridine, using [Mes-I-p-OEt-C6H5]BF4 to 
afford the product in 79% yield (20.3 mg, 0.07 mmol). 1H NMR (400 MHz, CDCl3) δ 
8.50 (d, J = 4.85 Hz, 1H), 7.37-7.47 (m, 4H), 7.30 (d, J = 7.59 Hz, 1H), 7.10 (q, 1H), 
7.01 (d, J = 8.64 Hz, 2H), 6.68 (d, J = 8.64 Hz, 2H), 3.96 (q, J = 6.9 Hz, 7.1 Hz, 2H), 
1.74 (s, 3H), 1.38 (t, J = 7.01 Hz, 3H); 13C NMR (125 MHz, CDCl3) δ 159.85, 157.99, 
146.66, 140.51, 139.44, 137.67, 133.60, 131.83, 130.46, 130.01, 129.67, 128.46, 
127.12, 122.17, 114.01, 63.45, 18.93, 14.96. HRMS C20H19NO [M+H]+ Expected: 
290.1540, Found: 290.1563.  
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2'-(3-methylpyridin-2-yl)-[1,1'-biphenyl]-4-carbaldehyde: General procedure C 
was followed on substrate 3-methyl-2-phenylpyridine, using [Mes-I-p-CHO-C6H5]BF4 
to afford the product in 77% yield (18.5 mg, 0.07 mmol). 1H NMR (400 MHz, CDCl3) δ 
9.94 (s, 1H), 8.47 (dd, J = 4.90 Hz, 1H), 7.68 (d, J = 8.53 Hz, 2H), 7.42-7.52 (m, 4H), 
7.33 (d, J = 7.86 Hz, 1H), 7.28 (d, J = 8.13 Hz, 2H), 7.12 (q, 1H), 1.80 (s, 3H); 13C 
NMR (125 MHz, CDCl3) δ 192.07, 158.90, 147.65, 146.78, 139.58, 137.95, 134.78, 
131.74, 130.26, 130.03, 129.75, 129.40, 128.72, 128.55, 122.58, 18.97. HRMS 
C19H15NO [M+H]+ Expected: 274.1227, Found: 274.1253.  
 
 
3-methyl-2-(4'-nitro-[1,1'-biphenyl]-2-yl)pyridine: General procedure C was 
followed on substrate 3-methyl-2-phenylpyridine, using [Mes-I-p-NO2-C6H5]BF4 to 
afford the product in 61% yield (15.6 mg, 0.05 mmol). 1H NMR (400 MHz, CDCl3) δ 
8.47 (dd, J = 4.96 Hz, 1H), 8.03 (dt, J = 8.95 Hz, 2H), 7.43-7.54 (m, 4H), 7.36 (d, J = 
7.53 Hz, 1H), 7.26-7.29 (m, 2H), 7.14 (q, 1H), 1.83 (s, 3H); 13C NMR (125 MHz, CDCl3) 
δ 158.49, 147.96, 146.81, 146.61, 139.58, 138.49, 137.85, 131.45, 130.16, 130.01, 
129.56, 128.79, 128.64, 123.07, 122.56, 18.85. HRMS C18H14N2O2 [M+H]+ Expected: 
291.1128, Found: 291.1110.  
 
 151 
 
3-methyl-2-(3'-nitro-[1,1'-biphenyl]-2-yl)pyridine: General procedure C was 
followed on substrate 3-methyl-2-phenylpyridine, using [Mes-I-m-NO2-C6H5]BF4 to 
afford the product in 69% yield (17.7 mg, 0.06 mmol). 1H NMR (400 MHz, CDCl3) δ 
8.48 (dd, J = 4.94 Hz, 1H), 8.01-8.05 (m, 2H), 7.41-7.55 (m, 5H), 7.37 (d, J = 7.7 Hz, 
1H), 7.31 (td, J = 7.9 Hz, 1H), 7.13 (q, 1H), 1.85 (s, 3H); 13C NMR (125 MHz, CDCl3) 
δ 158.58, 148.10, 146.93, 142.88, 139.63, 138.42, 138.08, 135.45, 131.66, 130.23, 
129.78, 128.92, 128.81, 128.76, 1224.17, 122.73, 121.78, 19.03. HRMS C18H14N2O2 
[M+H]+ Expected: 291.1128, Found: 291.1108.  
 
 
3-methyl-2-(2'-nitro-[1,1'-biphenyl]-2-yl)pyridine: General procedure C was 
followed on substrate 3-methyl-2-phenylpyridine, using [Mes-I-m-NO2-C6H5]BF4 to 
afford the product in 58% yield (14.9 mg, 0.05 mmol). 1H NMR (400 MHz, CDCl3) δ 
8.26 (dd, J = 4.7 Hz, 1H), 7.72 (dd, J = 8.1 Hz, 1H), 7.29-7.49 (m, 8H), 7.03 (q, 1H), 
2.09 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 157.59, 148.95, 146.21, 138.33, 137.16, 
136.06, 133.64, 132.41, 132.03, 129.92, 129.67, 128.44, 128.10, 127.96, 124.09, 
122.31, 19.10. HRMS C18H14N2O2 [M+H]+ Expected: 291.1128, Found: 291.1141. 
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2'-(3-methylpyridin-2-yl)-[1,1'-biphenyl]-2-carbaldehyde: General procedure C 
was followed on substrate 3-methyl-2-phenylpyridine, using [Mes-I-m-NO2-C6H5]BF4 
to afford the product in 18% yield (2.8 mg, 0.01 mmol). 1H NMR (400 MHz, CDCl3) δ 
9.94 (s, 1H), 8.34 (s, 1H), 7.82 (d, J = 7.75 Hz, 1H), 7.30-7.54 (m, 7H), 7.18 (d, J = 
7.58 Hz, 1H), 7.00-7.03 (m, 1H), 1.91 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 192.02, 
158.19, 146.63, 144.72, 140.62, 137.81, 137.04, 133.98, 132.82, 131.57, 131.41, 
129.90, 128.50, 128.10, 127.69, 126.95, 122.43, 29.85, 19.14. HRMS C19H15NO 
[M+H]+ Expected: 274.1227, Found: 274.1246.  
 
2-(4'-methoxy-[1,1'-biphenyl]-2-yl)-3-methylpyridine: General procedure C was 
followed on substrate 3-methyl-2-phenylpyridine, using [Mes-I-m-NO2-C6H5]BF4 to 
afford the product in 33% yield (8.1 mg, 0.03 mmol). 1H NMR (400 MHz, CDCl3) δ 8.51 
(dd, J = 5.09 Hz, 1H), 7.38-7.46 (m, 4H), 7.31 (dd, J = 8.1 Hz, 1H), 7.10 (q, 1H), 7.02-
7.04 (m, 2H), 6.69-6.71 (m, 2H), 3.75 (s, 3H), 1.75 (s, 3H); 13C NMR (125 MHz, CDCl3) 
δ 159.81, 158.63, 146.65, 140.46, 139.41, 137.74, 133.75, 131.86, 130.49, 130.03, 
129.71, 128.50. 
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